<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.transgene.com/wp-sitemap.xsl" ?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"><url><loc>https://www.transgene.com/june-17th-2014-letter-to-shareholders/</loc><lastmod>2017-10-02T22:29:15+02:00</lastmod></url><url><loc>https://www.transgene.com/corporate-presentation/</loc><lastmod>2017-10-02T23:30:04+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-fiscal-year-2013-results-and-provides-business-update/</loc><lastmod>2021-11-22T11:02:31+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-first-quarter-2014-financial-results-2/</loc><lastmod>2025-03-11T14:38:42+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-financial-results-for-first-six-months-of-2014-and-provides-update-on-tg4010-2/</loc><lastmod>2021-11-22T11:02:03+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-third-quarter-2014-financial-results/</loc><lastmod>2021-11-22T11:02:10+01:00</lastmod></url><url><loc>https://www.transgene.com/immunotherapy-for-non-small-cell-lung-cancer-current-approaches/</loc><lastmod>2025-11-12T16:24:48+01:00</lastmod></url><url><loc>https://www.transgene.com/comparative-analysis-of-immunization-schedules-using-a-novel-adenovirus-based-immunotherapeutic-targeting-hepatitis-b-in-naive-and-tolerant-mouse-models/</loc><lastmod>2025-11-12T16:24:39+01:00</lastmod></url><url><loc>https://www.transgene.com/33-tg1050-a-viral-vector-based-immunotherapeutic-designed-to-treat-chronic-hepatitis-b-induces-immune-responses-similar-to-those-display-by-hbv-resolving-patients-and-has-an-early-antiviral/</loc><lastmod>2019-07-03T11:43:30+02:00</lastmod></url><url><loc>https://www.transgene.com/pre-clinical-proof-of-concept-studies-exploring-schedules-of-administration-of-an-adenovirus-based-hbv-immunotherapeutic-show-wide-potential-for-induction-of-robust-and-long-lasting-t-cell-responses/</loc><lastmod>2025-11-12T16:25:13+01:00</lastmod></url><url><loc>https://www.transgene.com/130-a-multivalent-adenovirus-based-immunotherapeutic-for-treatment-of-chronic-hepatitis-b-induces-broad-robust-and-polyfunctional-t-cells-in-naive-and-hbv-tolerant-mice/</loc><lastmod>2025-11-12T16:25:19+01:00</lastmod></url><url><loc>https://www.transgene.com/fluorescent-tagged-vaccinia-virus-genome-allows-rapid-and-efficient-measurement-of-oncolytic-potential-and-discovery-of-oncolytic-modulators/</loc><lastmod>2026-01-05T23:19:45+01:00</lastmod></url><url><loc>https://www.transgene.com/efficacy-of-immunotherapy-with-tg4040-peg-interferon-and-ribavirin-in-a-phase-2-study-of-patients-with-chronic-hcv-infection-2/</loc><lastmod>2025-11-12T16:24:29+01:00</lastmod></url><url><loc>https://www.transgene.com/time-a-phase-2b3-evaluating-tg4010-in-combination-with-first-line-therapy-in-advanced-non-small-cell-lung-cancer-nsclc-phase-2b-results/</loc><lastmod>2025-11-12T16:24:13+01:00</lastmod></url><url><loc>https://www.transgene.com/tg4010-immunotherapy-combined-with-first-line-therapy-in-advanced-non-small-cell-lung-cancer-nsclc-phase-2b-results-of-the-time-study/</loc><lastmod>2025-11-12T16:24:21+01:00</lastmod></url><url><loc>https://www.transgene.com/tg1050-an-immunotherapeutic-to-treat-chronic-hepatitis-b-induces-robust-t-cells-and-exerts-an-antiviral-effect-in-hbv-persistent-mice/</loc><lastmod>2025-11-12T16:24:06+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-financial-calendar-for-2015/</loc><lastmod>2021-11-22T11:01:35+01:00</lastmod></url><url><loc>https://www.transgene.com/viral-hepatitis-hbv-cure-can-we-pin-our-hopes-on-immunotherapy/</loc><lastmod>2025-11-12T16:23:58+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-new-pre-clinical-data-with-tg4010-in-combination-with-immune-checkpoint-inhibitors-and-tg3003-humanized-mab-anti-cd115-to-be-presented-at-aacr/</loc><lastmod>2021-11-22T11:01:26+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-2014-financial-results-and-outlines-promising-clinical-pipeline-2/</loc><lastmod>2021-11-22T11:01:16+01:00</lastmod></url><url><loc>https://www.transgene.com/agreement-with-fda-announced-for-special-protocol-assessment-for-upcoming-phase-3-pexa-vec-trial-in-advanced-liver-cancer/</loc><lastmod>2021-11-22T11:00:48+01:00</lastmod></url><url><loc>https://www.transgene.com/immune-checkpoint-inhibitors-enhance-benefits-of-modified-vaccinia-virus-ankara-to-improve-survival-in-preclinical-models-of-cancer/</loc><lastmod>2025-11-12T16:23:42+01:00</lastmod></url><url><loc>https://www.transgene.com/the-mva-viral-platform-for-the-treatment-of-cancer-and-chronic-infectious-diseases-clinical-experience-from-four-randomized-controlled-phase-ii-studies/</loc><lastmod>2025-11-12T16:23:49+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-presents-new-pre-clinical-data-at-aacr-on-i-the-combination-of-tg4010-with-immune-checkpoint-inhibitors-ii-tg3003-an-anti-cd115-monoclonal-antibody/</loc><lastmod>2021-11-22T11:00:40+01:00</lastmod></url><url><loc>https://www.transgene.com/tg1050-a-novel-immunotherapeutic-to-treat-chronic-hepatitis-b-can-control-hbsag-and-provoke-hbsag-seroconversion-in-hbv-persistent-mouse-models/</loc><lastmod>2025-11-12T16:23:36+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-first-quarter-2015-financial-results/</loc><lastmod>2021-11-22T11:00:32+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-presents-new-data-with-tg1050-an-immunotherapy-being-developed-to-treat-chronic-hepatitis-b-at-the-international-liver-congress-2015/</loc><lastmod>2021-11-22T11:00:22+01:00</lastmod></url><url><loc>https://www.transgene.com/interview-of-philippe-archinard-on-tv-finance-in-french/</loc><lastmod>2017-10-02T22:50:45+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-participation-at-upcoming-investor-events/</loc><lastmod>2021-11-22T11:00:15+01:00</lastmod></url><url><loc>https://www.transgene.com/annual-general-meeting-on-11-june-2015/</loc><lastmod>2017-10-02T20:29:17+02:00</lastmod></url><url><loc>https://www.transgene.com/results-of-the-phase-2b-part-of-time-study-evaluating-tg4010-immunotherapy-in-stage-iv-non-small-cell-lung-cancer-nsclc-patients-receiving-first-line-chemotherapy/</loc><lastmod>2025-11-12T16:23:16+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-plans-restructuring-to-focus-on-research-and-development/</loc><lastmod>2021-11-22T11:00:07+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-oral-presentation-on-tg4010-cancer-immunotherapy-at-world-conference-on-lung-cancer/</loc><lastmod>2021-11-22T10:59:58+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-final-overall-survival-data-from-phase-2b-time-trial-with-tg4010-immunotherapy-in-non-small-cell-lung-cancer-presented-at-world-conference-on-lung-cancer/</loc><lastmod>2021-11-22T10:59:50+01:00</lastmod></url><url><loc>https://www.transgene.com/tg4010-immunotherapy-plus-chemotherapy-as-first-line-treatment-of-advanced-nsclc-phase-2b-results/</loc><lastmod>2025-11-12T16:23:07+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-financial-results-for-first-six-months-of-2015/</loc><lastmod>2021-11-22T10:59:42+01:00</lastmod></url><url><loc>https://www.transgene.com/recognition-of-core-derived-epitopes-from-a-novel-hbv-targeted-immunotherapeutic-by-t-cells-from-patients-infected-by-different-viral-genotypes/</loc><lastmod>2025-11-12T16:22:52+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-present-at-ladenburg-thalmann-2015-healthcare-conference-in-new-york/</loc><lastmod>2021-11-22T10:59:29+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-third-quarter-2015-financial-results/</loc><lastmod>2021-11-22T10:59:22+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-dosing-of-first-patient-with-tg1050-for-treatment-of-chronic-hepatitis-b-infection/</loc><lastmod>2021-11-22T10:59:10+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-sillajen-announce-revised-agreement-for-pexa-vec-oncolytic-viral-therapy-and-provide-update-on-clinical-development/</loc><lastmod>2021-11-22T10:59:00+01:00</lastmod></url><url><loc>https://www.transgene.com/tg4010-immunotherapy-plus-chemotherapy-as-first-line-treatment-of-advanced-nsclc-phase-2b-results-of-the-time-trial/</loc><lastmod>2025-11-12T16:10:06+01:00</lastmod></url><url><loc>https://www.transgene.com/a-novel-mva-based-multiphasic-vaccine-for-prevention-or-treatment-of-tuberculosis-induces-broad-and-multifunctional-cell-mediated-immunity-in-mice-and-primates/</loc><lastmod>2025-11-12T16:09:56+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-publication-in-the-lancet-oncology-of-phase-2b-time-trial-results-with-tg4010-immunotherapy-in-non-small-cell-lung-cancer/</loc><lastmod>2021-11-22T10:58:52+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-first-patient-randomized-in-multinational-phase-3-trial-for-pexa-vec-oncolytic-immunotherapy-in-advanced-liver-cancer/</loc><lastmod>2021-11-22T10:58:42+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-enters-new-phase-in-its-strategic-development/</loc><lastmod>2021-11-22T10:58:31+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-financial-calendar-for-2016/</loc><lastmod>2021-11-22T10:58:24+01:00</lastmod></url><url><loc>https://www.transgene.com/kempen-co-healthcare-life-sciences-conference-april-7-9-2016-amsterdam/</loc><lastmod>2017-10-02T15:22:54+02:00</lastmod></url><url><loc>https://www.transgene.com/eib-lends-eur-20m-totransgene/</loc><lastmod>2021-11-22T10:58:14+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-abl-announce-the-acquisition-by-abl-europe-of-transgenes-production-asset/</loc><lastmod>2021-11-22T10:58:02+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-participation-at-upcoming-investor-events-2/</loc><lastmod>2021-11-22T10:57:51+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-2015-financial-results-and-provides-outlook-for-2016/</loc><lastmod>2021-11-22T10:57:43+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-hires-two-senior-pharmaceutical-industry-executives-to-join-leadership-team/</loc><lastmod>2021-11-22T10:57:37+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-presents-pre-clinical-data-at-aacr-on-a-new-generation-oncolytic-viral-immunotherapy-armed-with-an-anti-pd1-monoclonal-antibody/</loc><lastmod>2021-11-22T10:57:31+01:00</lastmod></url><url><loc>https://www.transgene.com/vectorization-in-an-oncolytic-vaccinia-virus-of-an-antibody-a-fab-and-a-scfv-against-programmed-cell-death-1-pd-1-allow-their-intratumoral-delivery-and-an-improved-tumor-growth-inhibition/</loc><lastmod>2025-11-17T14:59:40+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-first-quarter-2016-business-update/</loc><lastmod>2021-11-22T10:57:22+01:00</lastmod></url><url><loc>https://www.transgene.com/composition-of-the-board-of-directors-and-statutory-auditors/</loc><lastmod>2021-11-22T10:57:14+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-poster-presentation-at-asco-annual-meeting-on-the-phase-3-phocus-clinical-trial-with-pexa-vec-oncolytic-immunotherapy/</loc><lastmod>2021-11-22T10:57:02+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-continue-phase-11b-study-with-tg1050-in-chronic-hepatitis-b-patients-on-the-recommendation-of-the-trials-safety-review-committee/</loc><lastmod>2021-11-22T10:57:07+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-participation-at-upcoming-investor-events-3/</loc><lastmod>2021-11-22T10:56:55+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-provides-an-update-on-its-development-strategy-and-on-its-first-half-year-2016-financials/</loc><lastmod>2021-11-22T10:56:43+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-presents-data-on-improved-cytotoxic-activity-of-oncolytic-viruses-expressing-intrabodies-in-resistant-tumor-cell-lines/</loc><lastmod>2021-11-22T10:56:31+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-collaboration-with-merck-and-pfizer-to-evaluate-the-combination-of-tg4001-with-avelumab-in-hpv-positive-head-neck-cancer-in-a-phase-12-study/</loc><lastmod>2021-11-22T10:56:25+01:00</lastmod></url><url><loc>https://www.transgene.com/first-patient-randomized-in-multiple-dose-cohort-of-phase-11b-trial-with-transgenes-tg1050-in-chronic-hepatitis-b-patients/</loc><lastmod>2021-11-22T10:56:17+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-third-quarter-2016-financial-results/</loc><lastmod>2021-11-22T10:55:57+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-publication-in-oncoimmunology-of-pre-clinical-data-demonstrating-delivery-of-a-fully-functional-immune-checkpoint-inhibitor-ici-with-anti-tumor-efficacy-by-a-new-generation-of-o/</loc><lastmod>2021-11-22T10:55:13+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-presents-preclinical-results-of-tg1050-an-hbv-targeted-immunotherapy-at-aasld-2016-liver-meeting/</loc><lastmod>2021-11-22T10:55:31+01:00</lastmod></url><url><loc>https://www.transgene.com/uc-davis-to-conduct-phase-2-trial-of-the-combination-of-tg4010-with-opdivo-nivolumab-for-2nd-line-treatment-of-metastatic-non-small-cell-lung-cancer-nsclc-the-trial-will-be-supported-by-tr/</loc><lastmod>2021-11-22T10:55:40+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-upcoming-investor-events/</loc><lastmod>2021-11-22T10:55:46+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-financial-calendar-for-2017/</loc><lastmod>2021-11-22T10:54:27+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-leon-berard-cancer-center-announce-dosing-of-the-first-patient-in-a-phase-1-immunotherapy-clinical-trial-evaluating-the-intra-tumoral-co-administration-of-pexa-vec-plus-ipilimumab-yervo/</loc><lastmod>2021-11-22T10:54:33+01:00</lastmod></url><url><loc>https://www.transgene.com/first-patient-dosed-in-phase-2-trial-evaluating-transgenes-tg4010-in-combination-with-opdivo-nivolumab-for-2nd-line-treatment-of-metastatic-non-small-cell-lung-cancer-nsclc/</loc><lastmod>2021-11-22T10:54:20+01:00</lastmod></url><url><loc>https://www.transgene.com/major-achievements-in-2016-validate-transgenes-strategy-and-provide-promising-outlook-for-2017/</loc><lastmod>2021-11-22T10:54:11+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-presents-very-promising-new-immunology-data-of-its-next-generation-armed-oncolytic-virus-at-the-aacr-annual-meeting-in-washington-dc/</loc><lastmod>2021-11-22T10:54:04+01:00</lastmod></url><url><loc>https://www.transgene.com/in-situ-biomarker-analysis-in-cancer-immunotherapy/</loc><lastmod>2025-11-12T16:08:30+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-upcoming-investor-meetings-and-rd-day/</loc><lastmod>2021-11-22T10:53:55+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-institut-bergonie-start-the-phase-2-part-of-the-metromajx-trial/</loc><lastmod>2021-11-22T10:53:46+01:00</lastmod></url><url><loc>https://www.transgene.com/marie-landel-and-maya-said-nominated-to-be-independent-members-of-transgenes-board-of-directors/</loc><lastmod>2021-11-22T10:53:37+01:00</lastmod></url><url><loc>https://www.transgene.com/sillajen-and-transgene-announce-the-enrollment-of-the-first-european-patient-in-multinational-phase-3-trial-for-pexa-vec-in-advanced-liver-cancer/</loc><lastmod>2021-11-22T10:53:26+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bristol-myers-squibb-announce-clinical-research-collaboration-to-evaluate-tg4010-in-combination-with-opdivo-and-standard-chemotherapy-in-first-line-non-small-cell-lung-cancer/</loc><lastmod>2021-11-22T10:53:17+01:00</lastmod></url><url><loc>https://www.transgene.com/e50-7-million-in-cash-and-cash-equivalents-as-of-march-31-2017/</loc><lastmod>2021-11-22T10:53:05+01:00</lastmod></url><url><loc>https://www.transgene.com/kempen-10th-life-sciences-conference-april-19-2017-amsterdam-netherlands/</loc><lastmod>2019-06-03T21:56:48+02:00</lastmod></url><url><loc>https://www.transgene.com/combined-general-meeting-of-june-8-2017/</loc><lastmod>2021-11-22T10:52:59+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-hosts-immuno-oncology-rd-day-focused-on-modulating-the-tumor-micro-environment-in-paris/</loc><lastmod>2021-11-22T10:52:52+01:00</lastmod></url><url><loc>https://www.transgene.com/servier-and-transgene-have-become-partners-to-apply-viral-vectorization-technology-to-the-engineering-of-allogenic-car-t/</loc><lastmod>2021-11-22T10:52:42+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-cancer-research-publication-confirming-the-potential-of-its-next-generation-armed-engineered-oncolytic-virus/</loc><lastmod>2021-11-22T10:52:32+01:00</lastmod></url><url><loc>https://www.transgene.com/first-patient-dosed-in-a-phase-12-trial-of-pexa-vec-opdivo-for-the-first-line-treatment-of-advanced-liver-cancer/</loc><lastmod>2021-11-22T10:52:24+01:00</lastmod></url><url><loc>https://www.transgene.com/first-half-year-2017-in-line-with-our-objectives-all-clinical-programs-progressing-and-new-collaboration-agreements-signed/</loc><lastmod>2021-11-22T10:51:49+01:00</lastmod></url><url><loc>https://www.transgene.com/radiotherapy-and-mva-muc1-il-2-vaccine-act-synergistically-for-inducing-specific-immunity-to-muc-1-tumor-antigen/</loc><lastmod>2025-11-12T16:08:41+01:00</lastmod></url><url><loc>https://www.transgene.com/tg1050-an-hbv-targeted-immunotherapeutics-efficiently-decreases-hbv-viremia-and-antigenemia-in-a-preclinical-model-a-meta-analysis-and-the-determination-of-the-involvement-of-cd4-and-cd8-t-cells/</loc><lastmod>2025-11-12T16:08:50+01:00</lastmod></url><url><loc>https://www.transgene.com/a-phase-ib-trial-of-jx-594-pexa-vec-a-targeted-multimechanistic-oncolytic-vaccinia-virus-in-combination-with-low-dose-cyclophosphamide-in-patients-with-advanced-solid-tumors/</loc><lastmod>2025-11-12T16:08:17+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-institut-bergonie-present-a-poster-on-the-metromajx-trial-oncolytic-virus-pexa-vec-metronomic-cyclophosphamide-at-esmo-2017-congress/</loc><lastmod>2021-11-22T10:52:13+01:00</lastmod></url><url><loc>https://www.transgene.com/improvement-of-mva-based-vaccines-by-expression-of-an-autophagy-inhibitor/</loc><lastmod>2025-11-12T16:09:22+01:00</lastmod></url><url><loc>https://www.transgene.com/evaluation-of-a-novel-oncolytic-raccoonpox-virus-expressing-the-bifunctional-fcu1-suicide-gene/</loc><lastmod>2025-11-12T16:09:02+01:00</lastmod></url><url><loc>https://www.transgene.com/a-phase-3-randomized-open-label-study-comparing-pexa-vec-vaccinia-gm-csf-thymidine-kinase-deactivated-virus-followed-by-sorafenib-versus-sorafenib-in-patients-with-advanced-hepatocellular-carcino/</loc><lastmod>2025-11-12T16:09:35+01:00</lastmod></url><url><loc>https://www.transgene.com/tg4010-immunotherapy-and-first-line-chemotherapy-for-advanced-non-small-cell-lung-cancer-time-results-from-the-phase-2b-part-of-a-randomised-double-blind-placebo-controlled-phase-2b3-trial/</loc><lastmod>2025-11-12T16:09:48+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-annonce-ses-prochaines-rencontres-avec-les-investisseurs/</loc><lastmod>2019-06-03T21:54:15+02:00</lastmod></url><url><loc>https://www.transgene.com/first-patient-treated-in-a-phase-1b2-trial-of-tg4001-in-combination-with-avelumab-in-hpv-positive-cancers-3/</loc><lastmod>2019-06-03T22:07:58+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-launches-invir-io-tm-its-integrated-platform-for-the-next-generation-of-multifunctional-oncolytic-viruses/</loc><lastmod>2019-06-05T16:56:00+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-randox-sign-collaboration-to-develop-innovative-multifunctional-oncolytic-virotherapies-for-solid-tumors-2/</loc><lastmod>2019-06-03T20:26:40+02:00</lastmod></url><url><loc>https://www.transgene.com/peer-reviewed-scientific-publications-highlight-tg4010s-ability-to-induce-broad-cd8-responses-and-its-synergistic-effects-in-combination-with-immune-checkpoint-inhibitors/</loc><lastmod>2019-07-03T17:40:00+02:00</lastmod></url><url><loc>https://www.transgene.com/third-quarter-marked-by-progress-in-clinical-development-and-research/</loc><lastmod>2019-07-03T16:50:54+02:00</lastmod></url><url><loc>https://www.transgene.com/tg1050-is-well-tolerated-and-induces-a-strong-specific-immune-response-in-patients-with-chronic-hepatitis-b/</loc><lastmod>2026-01-06T09:49:27+01:00</lastmod></url><url><loc>https://www.transgene.com/first-patient-treated-in-a-phase-12a-trial-oncovirac-of-novel-oncolytic-virus-tg6002-in-recurrent-glioblastoma/</loc><lastmod>2026-01-06T09:19:42+01:00</lastmod></url><url><loc>https://www.transgene.com/tg1050-is-well-tolerated-and-induces-a-strong-specific-immune-response-in-patients-with-chronic-hepatitis-b-2/</loc><lastmod>2025-11-12T16:07:51+01:00</lastmod></url><url><loc>https://www.transgene.com/sequential-administration-of-mva-based-vaccines-and-pd-1pd-l1-blocking-antibodies-confers-measurable-benefits-on-tumor-growth-and-survival-preclinical-studies-with-mva-%ce%b2gal-and-mva-muc1-tg4010/</loc><lastmod>2025-11-12T16:08:06+01:00</lastmod></url><url><loc>https://www.transgene.com/viral-based-vaccine-tg4010-induces-broadening-of-specific-immune-response-and-improves-outcome-in-advanced-nsclc/</loc><lastmod>2025-11-12T16:07:58+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-receives-fda-ind-approval-to-begin-a-clinical-trial-with-tg4010-nivolumab-chemotherapy-in-the-first-line-treatment-of-lung-cancer-nsclc-2/</loc><lastmod>2021-11-22T10:51:59+01:00</lastmod></url><url><loc>https://www.transgene.com/bioinvent-and-transgene-collaborate-on-next-generation-oncolytic-viruses-encoding-an-anti-ctla-4-antibody-to-treat-solid-tumors/</loc><lastmod>2019-06-03T19:51:59+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-upcoming-investor-meetings-2/</loc><lastmod>2019-06-03T19:52:45+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-financial-calendar-for-2018/</loc><lastmod>2019-06-03T19:52:13+02:00</lastmod></url><url><loc>https://www.transgene.com/first-patient-dosed-in-a-phase-2-trial-with-transgenes-tg4010-nivolumab-chemotherapy-for-the-first-line-treatment-of-lung-cancer-nsclc/</loc><lastmod>2021-11-22T10:51:27+01:00</lastmod></url><url><loc>https://www.transgene.com/first-chronic-hepatitis-b-patient-dosed-in-china-in-a-phase-1-trial-of-t101-transgenes-tg1050-technology/</loc><lastmod>2026-01-06T09:49:17+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-present-data-on-a-novel-viral-vector-with-superior-anti-cancer-immunotherapeutic-activity-at-aacr-2018/</loc><lastmod>2019-06-03T19:52:41+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-announce-major-clinical-results-in-2018-and-achieve-promising-progress-on-its-new-oncolytic-viruses/</loc><lastmod>2019-06-03T22:33:22+02:00</lastmod></url><url><loc>https://www.transgene.com/h-c-wainwright-global-life-sciences-conference-april-9-2018-monte-carlo-monaco/</loc><lastmod>2018-05-29T09:38:14+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-presents-data-on-a-novel-viral-vector-with-remarkable-anticancer-activity-at-aacr-2018/</loc><lastmod>2019-06-03T19:44:15+02:00</lastmod></url><url><loc>https://www.transgene.com/pseudocowpox-a-next-generation-viral-vector-for-cancer-immunotherapy/</loc><lastmod>2025-11-12T16:07:45+01:00</lastmod></url><url><loc>https://www.transgene.com/e35-6-million-in-cash-and-cash-equivalents-as-of-march-31-2018/</loc><lastmod>2021-11-22T10:51:16+01:00</lastmod></url><url><loc>https://www.transgene.com/availability-of-preparatory-documents-for-the-combined-general-meeting-ordinary-and-extraordinary-sessions-of-may-23-2018/</loc><lastmod>2019-06-03T19:44:23+02:00</lastmod></url><url><loc>https://www.transgene.com/a-multi-antigenic-mva-vaccine-increases-efficacy-of-combination-chemotherapy-against-mycobacterium-tuberculosis/</loc><lastmod>2025-11-12T16:07:32+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-present-new-clinical-data-on-oncolytic-virus-pexa-vec-at-asco-2018/</loc><lastmod>2021-11-22T10:51:05+01:00</lastmod></url><url><loc>https://www.transgene.com/single-intravenous-preoperative-administration-of-the-oncolytic-virus-pexa-vec-to-prime-anti-tumor-immunity/</loc><lastmod>2025-11-12T16:07:24+01:00</lastmod></url><url><loc>https://www.transgene.com/combined-general-meeting-of-may-23-2018/</loc><lastmod>2019-06-03T19:44:40+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-upcoming-investor-meetings-3/</loc><lastmod>2021-11-22T10:50:51+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-upcoming-investor-meetings-3-2/</loc><lastmod>2019-06-03T19:44:55+02:00</lastmod></url><url><loc>https://www.transgene.com/therapeutic-cancer-vaccines-in-the-treatment-of-non-small-cell-lung-cancer-2/</loc><lastmod>2025-11-12T16:26:00+01:00</lastmod></url><url><loc>https://www.transgene.com/randomized-dose-finding-clinical-trial-of-oncolytic-immunotherapeutic-vaccinia-jx-594-in-liver-cancer-2/</loc><lastmod>2025-11-12T16:25:52+01:00</lastmod></url><url><loc>https://www.transgene.com/oncolytic-and-immunotherapeutic-vaccinia-induces-antibody-mediated-complement-dependent-cancer-cell-lysis-in-humans-2/</loc><lastmod>2025-11-12T16:25:42+01:00</lastmod></url><url><loc>https://www.transgene.com/phase-ib-dose-escalation-study-of-pexa-vec-pexastimogene-devacirepvec-jx-594-an-oncolytic-and-immunotherapeutic-vaccinia-virus-administered-by-intravenous-iv-infusions-in-patients-with-metastat-2/</loc><lastmod>2025-11-12T16:54:30+01:00</lastmod></url><url><loc>https://www.transgene.com/phase-ii-trial-of-pexa-vec-pexastimogene-devacirepvec-jx-594-an-oncolytic-and-immunotherapeutic-vaccinia-virus-followed-by-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma-hcc-2/</loc><lastmod>2026-01-06T09:44:32+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-tasly-biopharmaceuticals-conclude-strategic-agreements-for-the-rights-of-tg6002-and-tg1050-in-greater-china/</loc><lastmod>2026-01-06T09:49:07+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-tasly-biopharmaceuticals-conclude-strategic-agreements-for-the-rights-of-tg6002-and-tg1050-in-greater-china-3/</loc><lastmod>2026-01-06T09:48:48+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-tasly-biopharmaceuticals-conclude-strategic-agreements-for-the-rights-of-tg6002-and-tg1050-in-greater-china-4/</loc><lastmod>2019-06-03T19:46:00+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-presents-2018-half-year-results-and-business-update/</loc><lastmod>2019-06-03T19:46:08+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-unveils-myvac-tm-an-individualized-immunotherapy-against-solid-tumors/</loc><lastmod>2019-06-05T16:49:54+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-present-its-viral-vector-expertise-at-the-society-for-immunotherapy-of-cancer-conference/</loc><lastmod>2019-06-03T19:46:22+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-present-positive-results-from-phase-1b-trial-of-tg1050-in-patients-with-chronic-hepatitis-b-at-upcoming-aasld-liver-meeting-2018/</loc><lastmod>2026-01-06T09:48:37+01:00</lastmod></url><url><loc>https://www.transgene.com/first-patient-dosed-in-a-phase-1-2-trial-of-transgenes-oncolytic-virus-tg6002-administered-intravenously-in-patients-with-advanced-gastrointestinal-tumors/</loc><lastmod>2026-01-06T09:18:25+01:00</lastmod></url><url><loc>https://www.transgene.com/e26-6-million-in-cash-and-cash-equivalents-as-of-september-30-2018/</loc><lastmod>2019-06-03T19:46:43+02:00</lastmod></url><url><loc>https://www.transgene.com/nec-and-transgene-announce-a-collaboration-in-the-field-of-individualized-cancer-immunotherapy-leveraging-necs-ai-and-transgenes-myvac-platform/</loc><lastmod>2019-06-03T19:46:51+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-present-positive-data-at-the-sitc-supporting-the-co-development-of-a-next-generation-oncolytic-virus-encoding-for-an-anti-ctla-4-antibody/</loc><lastmod>2019-06-03T19:40:34+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-highlights-its-broad-viral-vector-expertise-at-the-society-for-immunotherapy-of-cancer-sitc-2018-conference/</loc><lastmod>2020-04-03T08:29:57+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-positive-results-from-phase-1-clinical-trial-of-tg1050-in-chronic-hepatitis-b-presented-at-the-aasld-liver-meeting-2018/</loc><lastmod>2026-01-06T09:48:12+01:00</lastmod></url><url><loc>https://www.transgene.com/pseudocowpox-virus-pcpv-a-potent-viral-vector-for-both-antigen-dependent-and-independent-cancer-immunotherapy/</loc><lastmod>2025-11-12T16:07:14+01:00</lastmod></url><url><loc>https://www.transgene.com/myvac-tm-viral-based-vaccine-for-personalized-neoantigen-directed-cancer-therapy/</loc><lastmod>2019-07-01T15:07:38+02:00</lastmod></url><url><loc>https://www.transgene.com/safety-and-immunogenicity-of-single-and-multiple-injections-of-the-therapeutic-vaccine-tg1050-in-nuc-suppressed-chronic-hepatitis-b-chb-patients-unblinded-analysis-of-a-double-blind-placebo-contro/</loc><lastmod>2026-01-06T09:48:24+01:00</lastmod></url><url><loc>https://www.transgene.com/investigational-treatment-combining-tg1050-an-hbv-specific-immunotherapeutic-with-direct-acting-antivirals-or-immunomodulators-improves-sustained-antiviral-effects-and-immune-responses-in-hbv-persi/</loc><lastmod>2026-01-06T09:47:52+01:00</lastmod></url><url><loc>https://www.transgene.com/2018-half-year-results-and-business-update/</loc><lastmod>2019-03-07T18:12:09+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-upcoming-investor-meetings-4/</loc><lastmod>2019-06-03T19:41:04+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-presente-son-calendrier-de-communication-financiere-pour-2019/</loc><lastmod>2021-11-22T10:50:32+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-completes-safety-and-tolerability-assessment-of-tg4001-in-combination-with-avelumab-in-phase-1b-part-of-trial-in-hpv-positive-cancer-patients-2/</loc><lastmod>2019-06-03T19:41:19+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-a-positive-2018-moving-ahead-with-a-strong-portfolio/</loc><lastmod>2019-06-04T18:07:52+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-extend-their-collaboration-to-develop-multifunctional-oncolytic-viruses-for-the-treatment-of-solid-tumors/</loc><lastmod>2019-06-03T19:41:50+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-secures-a-e20-million-revolving-credit-facility-with-natixis/</loc><lastmod>2019-06-03T19:41:38+02:00</lastmod></url><url><loc>https://www.transgene.com/neoviva-project-supporting-the-development-of-myvac-awarded-a-e5-2-million-grant-from-bpifrances-investments-for-the-future-programme/</loc><lastmod>2020-04-23T15:55:09+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-start-clinical-development-of-lead-myvac-individualized-immunotherapy-tg4050-in-2019-under-its-partnership-with-nec/</loc><lastmod>2020-04-23T15:55:24+02:00</lastmod></url><url><loc>https://www.transgene.com/advancing-our-pipeline/</loc><lastmod>2026-09-02T18:03:03+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-extend-their-collaboration-to-develop-multifunctional-oncolytic-viruses-for-the-treatment-of-solid-tumors-2/</loc><lastmod>2021-11-22T10:50:04+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-extend-their-collaboration-to-develop-multifunctional-oncolytic-viruses-for-the-treatment-of-solid-tumors-2-2-2/</loc><lastmod>2021-11-22T10:49:54+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-extend-their-collaboration-to-develop-multifunctional-oncolytic-viruses-for-the-treatment-of-solid-tumors-2-2-2-2/</loc><lastmod>2021-11-22T10:49:32+01:00</lastmod></url><url><loc>https://www.transgene.com/financial-visibility-extended-to-q4-2020-including-10-million-revenue-from-collaboration-with-astrazeneca-to-be-received-in-q2-2019/</loc><lastmod>2021-11-22T10:49:21+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-extend-their-collaboration-to-develop-multifunctional-oncolytic-viruses-for-the-treatment-of-solid-tumors-2-2-2-2-2-2/</loc><lastmod>2021-11-22T10:49:11+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-extend-their-collaboration-to-develop-multifunctional-oncolytic-viruses-for-the-treatment-of-solid-tumors-2-2-2-2-2-2-2/</loc><lastmod>2021-11-22T10:48:55+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-upcoming-investor-meetings-5/</loc><lastmod>2019-06-03T19:37:19+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-presents-first-clinical-data-indicating-that-tg1050-induces-a-robust-and-hbv-specific-cell-mediated-immune-response-in-patients-with-chronic-hepatitis-b/</loc><lastmod>2026-01-06T09:49:39+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-launches-a-capital-increase-by-way-of-an-accelerated-book-build-offering/</loc><lastmod>2019-06-05T17:30:38+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-successfully-raises-e-14-4-million-from-u-s-and-european-investors/</loc><lastmod>2019-06-05T17:34:40+02:00</lastmod></url><url><loc>https://www.transgene.com/successful-completion-of-transgenes-rights-issue-gross-proceeds-of-circa-e46-4-million/</loc><lastmod>2021-11-22T10:55:22+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-rights-issue/</loc><lastmod>2021-11-22T10:56:07+01:00</lastmod></url><url><loc>https://www.transgene.com/peer-reviewed-publications-confirm-the-potential-of-transgenes-tg4001-and-tg6002/</loc><lastmod>2021-11-22T10:48:45+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-positive-new-results-presented-at-asco-from-phase-2b-time-trial-with-tg4010-immunotherapy-in-non-small-cell-lung-cancer-poster/</loc><lastmod>2019-06-05T17:57:51+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-the-launch-of-a-rights-issue/</loc><lastmod>2019-06-19T15:13:59+02:00</lastmod></url><url><loc>https://www.transgene.com/tg1050-a-novel-immunotherapeutic-to-treat-chronic-hepatitis-b-can-control-hbsag-and-provoke-hbsag-seroconversion-in-hbv-persistent-mouse-models-2-2/</loc><lastmod>2026-01-06T09:50:05+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-the-launch-of-a-rights-issue-2/</loc><lastmod>2019-07-02T19:06:48+02:00</lastmod></url><url><loc>https://www.transgene.com/33-tg1050-a-viral-vector-based-immunotherapeutic-designed-to-treat-chronic-hepatitis-b-induces-immune-responses-similar-to-those-display-by-hbv-resolving-patients-and-has-an-early-antiviral-2/</loc><lastmod>2026-01-06T09:50:22+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-receives-mhra-approval-for-lead-myvac-individualized-immunotherapy-tg4050-to-commence-clinical-development-in-hpv-negative-head-and-neck-cancers-in-the-uk/</loc><lastmod>2021-11-22T10:48:23+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-receives-mhra-approval-for-a-clinical-trial-of-tg6002-a-next-generation-oncolytic-virus-administered-by-intrahepatic-artery-infusion-in-patients-with-colorectal-cancer-with-liver-metastase/</loc><lastmod>2021-11-22T10:48:11+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-provides-update-on-phocus-study-of-pexa-vec-in-liver-cancer-following-planned-interim-futility-analysis/</loc><lastmod>2021-11-22T10:48:32+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-provides-an-update-after-the-interim-futility-analysis-of-the-phocus-study-of-pexa-vec-in-liver-cancer/</loc><lastmod>2021-11-22T10:48:02+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-upcoming-investor-meetings/</loc><lastmod>2019-08-30T10:59:38+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-confirms-the-timeline-of-its-clinical-news-flow-and-presents-2019-half-year-results/</loc><lastmod>2021-11-22T10:47:36+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-receives-approval-from-the-french-health-authority-ansm-to-initiate-two-clinical-trials-of-its-lead-myvac-individualized-immunotherapy-tg4050/</loc><lastmod>2021-11-22T10:47:51+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-first-promising-efficacy-results-with-tg4001-in-combination-with-avelumab-in-hpv-positive-cancer-at-esmo-2019/</loc><lastmod>2021-11-22T10:47:27+01:00</lastmod></url><url><loc>https://www.transgene.com/tg4001-avelumabphase1b-2-results/</loc><lastmod>2021-10-05T11:03:19+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-will-participate-in-the-jefferies-2019-london-healthcare-conference/</loc><lastmod>2021-11-22T10:47:13+01:00</lastmod></url><url><loc>https://www.transgene.com/meta-analysis-of-two-phase-1b-randomized-double-blind-placebo-controlled-clinical-trials-of-the-hbv-therapeutic-vaccines-tg1050-and-t101-developed-in-europe-canada-or-china/</loc><lastmod>2025-11-12T16:34:05+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-provides-q3-2019-business-update-with-focus-on-recently-announced-efficacy-results-of-tg4001/</loc><lastmod>2021-11-22T10:47:02+01:00</lastmod></url><url><loc>https://www.transgene.com/non-clinical-and-clinical-safety-of-mva-based-immunotherapy-products-targeting-cancer-and-infectious-diseases/</loc><lastmod>2025-11-12T16:05:31+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-investor-meetings-for-january-2020/</loc><lastmod>2021-11-22T10:46:51+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-announce-compelling-preclinical-data-for-bt-001-in-solid-tumors/</loc><lastmod>2021-11-22T10:46:43+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-on-the-combination-trial-of-tg4010-chemotherapy-and-nivolumab-in-non-small-cell-lung-cancer/</loc><lastmod>2021-11-22T10:46:17+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-financial-calendar-for-2020/</loc><lastmod>2022-03-18T16:34:28+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-nec-start-two-clinical-trials-with-tg4050-an-individualized-ai-powered-cancer-vaccine-for-ovarian-and-head-neck-cancers/</loc><lastmod>2021-11-22T10:45:48+01:00</lastmod></url><url><loc>https://www.transgene.com/third-quarter-2026-financial-results/</loc><lastmod>2026-01-27T15:39:29+01:00</lastmod></url><url><loc>https://www.transgene.com/first-patient-dosed-with-transgenes-oncolytic-virus-tg6002-administered-by-intrahepatic-artery-infusion-in-colorectal-cancer-with-liver-metastases/</loc><lastmod>2026-01-06T09:17:59+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-to-present-data-on-bt-001-an-oncolytic-virus-encoding-for-an-anti-ctla4-antibody-at-upcoming-congresses/</loc><lastmod>2021-11-22T10:45:27+01:00</lastmod></url><url><loc>https://www.transgene.com/major-rd-milestones-achieved-in-2019-and-strong-clinical-activity-in-2020/</loc><lastmod>2021-11-22T10:45:13+01:00</lastmod></url><url><loc>https://www.transgene.com/availability-of-transgenes-2019-universal-registration-document-and-update-on-the-effect-of-covid-19/</loc><lastmod>2021-11-22T10:44:50+01:00</lastmod></url><url><loc>https://www.transgene.com/availability-of-preparatory-documents-for-the-combined-general-meeting-of-may-27-2020/</loc><lastmod>2021-11-22T10:45:03+01:00</lastmod></url><url><loc>https://www.transgene.com/vaxxel-acquires-transgenes-duckcelt-t17-cell-line-to-develop-industrial-scale-vaccines-against-respiratory-viruses/</loc><lastmod>2021-11-22T10:44:36+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-q1-2020-financial-position-and-business-update/</loc><lastmod>2021-11-22T10:44:17+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-nec-demonstrate-high-accuracy-of-ai-based-neoantigen-prediction-for-the-design-of-individualized-cancer-vaccine-tg4050/</loc><lastmod>2020-05-14T17:13:26+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-present-preclinical-data-demonstrating-bt-001s-powerful-activity-against-solid-tumors/</loc><lastmod>2021-11-22T10:44:01+01:00</lastmod></url><url><loc>https://www.transgene.com/combined-general-meeting-of-may-27-2020/</loc><lastmod>2021-11-22T10:43:54+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-presents-promising-new-data-from-its-next-generation-immunotherapy-platforms-at-aacr-2020/</loc><lastmod>2021-11-22T10:43:45+01:00</lastmod></url><url><loc>https://www.transgene.com/transgenes-and-bioinvents-bt-001-achieves-outstanding-tumor-cure-rates-in-preclinical-models/</loc><lastmod>2021-11-22T10:43:37+01:00</lastmod></url><url><loc>https://www.transgene.com/performance-of-neoantigen-prediction-for-the-design-of-tg4050-a-patient-specific-neoantigen-cancer-vaccine/</loc><lastmod>2025-12-17T10:49:20+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-present-additional-immunology-data-from-the-time-trial-with-tg4010-in-patients-with-advanced-lung-cancer-at-sitc-2017/</loc><lastmod>2020-06-25T16:55:58+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-hypertrust-patient-data-care-announce-successful-go-live-of-the-worlds-first-blockchain-solution-for-clinical-trials-of-personalized-healthcare/</loc><lastmod>2021-11-22T10:43:29+01:00</lastmod></url><url><loc>https://www.transgene.com/design-of-an-innovative-model-to-improve-anticancer-therapeutic-treatment-based-on-a-vascularized-3d-organoids-derived-from-patients-lung-tumors-for-the-purpose-of-precision-medicine/</loc><lastmod>2026-01-06T01:05:50+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-results-from-clinical-study-of-tg4001-in-combination-with-avelumab-in-advanced-hpv-positive-cancers/</loc><lastmod>2021-11-22T10:43:22+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-receives-22-2-million-from-the-sale-of-part-of-its-minority-stake-in-tasly-biopharmaceuticals/</loc><lastmod>2021-11-22T10:43:14+01:00</lastmod></url><url><loc>https://www.transgene.com/positive-initial-data-from-a-phase-1-trial-with-transgenes-oncolytic-virus-tg6002/</loc><lastmod>2026-01-06T09:17:34+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-upcoming-investor-meetings-6/</loc><lastmod>2021-11-22T10:42:59+01:00</lastmod></url><url><loc>https://www.transgene.com/positive-clinical-results-for-tg4001-and-tg6002-and-financial-visibility-secured-until-2022/</loc><lastmod>2021-11-22T10:42:45+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-nec-and-bostongene-announce-strategic-collaboration-for-two-ongoing-clinical-trials-for-patients-with-ovarian-and-head-neck-cancers/</loc><lastmod>2021-11-22T10:42:35+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-to-present-data-on-oncolytic-virus-bt-001-at-the-sitc-35th-anniversary-annual-meeting/</loc><lastmod>2021-11-22T10:42:23+01:00</lastmod></url><url><loc>https://www.transgene.com/acceptance-of-late-breaking-abstract-at-upcoming-sitc-2020-conference-on-the-detailed-results-from-clinical-study-of-tg4001-in-combination-with-avelumab-in-advanced-hpv-positive-cancers/</loc><lastmod>2021-11-22T10:42:17+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-detailed-results-from-clinical-study-of-tg4001-in-combination-with-avelumab-in-advanced-hpv-positive-cancers/</loc><lastmod>2021-11-22T10:42:11+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-presents-its-individualized-immunotherapy-tg4050-at-the-annual-neoantigen-based-therapies-summit/</loc><lastmod>2021-11-22T10:42:05+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-business-update-and-end-q3-2020-financial-position/</loc><lastmod>2021-11-22T10:41:58+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-presents-e-poster-outlining-detailed-results-from-the-phase-1b-2-trial-of-tg4001-in-combination-with-avelumab-in-advanced-hpv-positive-cancers-at-sitc-2020/</loc><lastmod>2021-11-22T10:41:51+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-present-data-on-next-generation-oncolytic-virus-bt-001-at-the-sitc-35th-anniversary-annual-meeting/</loc><lastmod>2021-11-22T10:41:44+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-appoints-hedi-ben-brahim-as-chairman-and-chief-executive-officer/</loc><lastmod>2021-11-22T10:41:35+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-present-phase-1b-2-trial-results-of-tg4001-in-combination-with-avelumab-in-advanced-hpv-positive-cancers-at-esmo-io-2020/</loc><lastmod>2021-11-22T10:41:27+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-investor-meetings-for-january-2021/</loc><lastmod>2021-11-22T10:41:14+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-financial-calendar-for-2021/</loc><lastmod>2021-11-22T10:41:07+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-receive-cta-approval-for-phase-1-2a-trial-of-oncolytic-virus-bt-001-in-solid-tumors/</loc><lastmod>2022-03-18T16:32:45+01:00</lastmod></url><url><loc>https://www.transgene.com/first-quarter-2026-financial-results/</loc><lastmod>2026-09-24T18:41:15+02:00</lastmod></url><url><loc>https://www.transgene.com/2025-full-year-results/</loc><lastmod>2026-01-27T17:48:00+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-appoints-gaelle-stadtler-as-director-of-human-resources/</loc><lastmod>2021-11-22T10:40:49+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-receive-approval-from-ansm-to-proceed-with-phase-i-iia-trial-of-anti-ctla4-armed-oncolytic-virus-bt-001-in-solid-tumors/</loc><lastmod>2021-11-22T10:40:36+01:00</lastmod></url><url><loc>https://www.transgene.com/first-head-neck-cancer-patient-treated-in-france-in-a-phase-i-trial-with-tg4050-myvac-platform-transgenes-innovative-individualized-immunotherapy/</loc><lastmod>2021-11-22T10:40:26+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-have-enrolled-first-patient-in-phase-i-iia-trial-of-novel-oncolytic-virus-bt-001-in-solid-tumors/</loc><lastmod>2021-11-22T10:39:26+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-present-its-immuno-oncology-expertise-at-upcoming-scientific-conferences/</loc><lastmod>2021-11-22T10:39:18+01:00</lastmod></url><url><loc>https://www.transgene.com/significant-milestones-achieved-on-all-drug-candidates-in-2020-and-financial-visibility-until-2022/</loc><lastmod>2021-11-22T10:39:08+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-expands-phase-ii-clinical-trial-of-therapeutic-vaccine-tg4001-in-combination-with-avelumab-versus-avelumab-monotherapy-in-patients-with-hpv16-positive-anogenital-cancers/</loc><lastmod>2021-11-22T10:38:43+01:00</lastmod></url><url><loc>https://www.transgene.com/availability-of-transgenes-2020-universal-registration-document/</loc><lastmod>2021-11-22T10:38:20+01:00</lastmod></url><url><loc>https://www.transgene.com/availability-of-preparatory-documents-for-the-combined-general-meeting-of-may-26-2021/</loc><lastmod>2021-11-22T10:38:12+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-presents-initial-phase-i-data-of-tg6002-highlighting-the-potential-of-the-intravenous-administration-of-its-oncolytic-viruses/</loc><lastmod>2026-01-06T09:16:38+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-upcoming-investor-meetings-7/</loc><lastmod>2021-11-22T10:37:53+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-business-update-and-end-q1-2021-financial-position/</loc><lastmod>2021-11-22T10:37:42+01:00</lastmod></url><url><loc>https://www.transgene.com/immunocompetent-cancer-on-chip-models-to-assess-immuno-oncology-therapy/</loc><lastmod>2025-11-12T16:03:23+01:00</lastmod></url><url><loc>https://www.transgene.com/modified-vaccinia-virus-ankara-based-vaccines-in-the-era-of-personalized-immunotherapy-of-cancer/</loc><lastmod>2025-12-17T10:49:59+01:00</lastmod></url><url><loc>https://www.transgene.com/combined-general-meeting-of-may-26-2021/</loc><lastmod>2021-11-22T10:37:31+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-receive-ind-approval-from-the-u-s-fda-for-bt-001-a-novel-oncolytic-virus-for-the-treatment-of-solid-tumors/</loc><lastmod>2021-11-22T10:37:18+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-strengthens-global-ip-protection-for-its-novel-invir-io-oncolytic-viruses-encoding-immune-checkpoint-inhibitors-icis/</loc><lastmod>2021-11-22T10:37:08+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-launches-a-capital-increase-via-a-private-placement/</loc><lastmod>2021-11-22T10:36:59+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-the-success-of-its-capital-increase-via-a-private-placement/</loc><lastmod>2021-11-22T10:32:22+01:00</lastmod></url><url><loc>https://www.transgene.com/first-patient-enrolled-in-expanded-phase-ii-clinical-trial-of-tg4001-avelumab-vs-avelumab-alone-in-patients-with-hpv16-positive-anogenital-cancers-2/</loc><lastmod>2022-03-18T16:28:23+01:00</lastmod></url><url><loc>https://www.transgene.com/first-head-neck-cancer-patient-enrolled-in-the-uk-in-a-phase-i-trial-with-tg4050-myvac-platform-transgenes-innovative-individualized-immunotherapy-2/</loc><lastmod>2022-03-17T18:13:21+01:00</lastmod></url><url><loc>https://www.transgene.com/first-patient-enrolled-in-expanded-phase-ii-clinical-trial-of-tg4001-avelumab-vs-avelumab-alone-in-patients-with-hpv16-positive-anogenital-cancers-4/</loc><lastmod>2022-03-17T18:07:22+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-upcoming-investor-meetings-8/</loc><lastmod>2026-07-09T15:53:49+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-presents-data-from-phase-i-clinical-trial-confirming-the-potential-of-the-oncolytic-virus-tg6002/</loc><lastmod>2026-07-09T15:53:17+02:00</lastmod></url><url><loc>https://www.transgene.com/first-patient-enrolled-in-expanded-phase-ii-clinical-trial-of-tg4001-avelumab-vs-avelumab-alone-in-patients-with-hpv16-positive-anogenital-cancers-3/</loc><lastmod>2026-07-09T15:51:51+02:00</lastmod></url><url><loc>https://www.transgene.com/home-actus/</loc><lastmod>2026-01-09T10:33:42+01:00</lastmod></url><url><loc>https://www.transgene.com/management-committee/</loc><lastmod>2026-03-26T18:39:54+01:00</lastmod></url><url><loc>https://www.transgene.com/christophe-ancel/</loc><lastmod>2025-12-17T09:25:58+01:00</lastmod></url><url><loc>https://www.transgene.com/lucie-larguier/</loc><lastmod>2026-03-10T16:24:25+01:00</lastmod></url><url><loc>https://www.transgene.com/steven-bloom/</loc><lastmod>2025-12-15T23:06:47+01:00</lastmod></url><url><loc>https://www.transgene.com/john-felitti/</loc><lastmod>2025-12-17T08:57:50+01:00</lastmod></url><url><loc>https://www.transgene.com/gaelle-stadtler/</loc><lastmod>2025-12-15T22:53:16+01:00</lastmod></url><url><loc>https://www.transgene.com/philippe-archinard/</loc><lastmod>2025-10-12T13:58:08+02:00</lastmod></url><url><loc>https://www.transgene.com/board-of-directors/</loc><lastmod>2026-05-22T17:57:00+02:00</lastmod></url><url><loc>https://www.transgene.com/jean-luc-belingard/</loc><lastmod>2025-10-12T19:58:38+02:00</lastmod></url><url><loc>https://www.transgene.com/benoit-habert/</loc><lastmod>2025-10-12T21:57:29+02:00</lastmod></url><url><loc>https://www.transgene.com/marie-landel/</loc><lastmod>2025-12-09T16:42:53+01:00</lastmod></url><url><loc>https://www.transgene.com/alain-merieux/</loc><lastmod>2025-12-17T09:08:45+01:00</lastmod></url><url><loc>https://www.transgene.com/maya-said/</loc><lastmod>2025-10-12T22:19:18+02:00</lastmod></url><url><loc>https://www.transgene.com/tsgh/</loc><lastmod>2025-10-12T22:39:26+02:00</lastmod></url><url><loc>https://www.transgene.com/pipeline/</loc><lastmod>2024-02-06T15:59:41+01:00</lastmod></url><url><loc>https://www.transgene.com/produits-tg4050-teaser/</loc><lastmod>2026-07-07T14:28:02+02:00</lastmod></url><url><loc>https://www.transgene.com/produits-bt-001-teaser/</loc><lastmod>2025-12-09T14:42:41+01:00</lastmod></url><url><loc>https://www.transgene.com/faq/</loc><lastmod>2025-09-22T16:33:43+02:00</lastmod></url><url><loc>https://www.transgene.com/therapeutic-vaccines/</loc><lastmod>2023-08-31T11:45:15+02:00</lastmod></url><url><loc>https://www.transgene.com/oncolytic-viruses/</loc><lastmod>2024-04-18T13:57:00+02:00</lastmod></url><url><loc>https://www.transgene.com/myvac/</loc><lastmod>2024-04-12T08:05:28+02:00</lastmod></url><url><loc>https://www.transgene.com/invirio/</loc><lastmod>2023-09-04T17:21:18+02:00</lastmod></url><url><loc>https://www.transgene.com/publications-lien/</loc><lastmod>2025-09-22T16:31:02+02:00</lastmod></url><url><loc>https://www.transgene.com/tg4050-1/</loc><lastmod>2021-10-05T19:01:04+02:00</lastmod></url><url><loc>https://www.transgene.com/bt-001/</loc><lastmod>2026-03-23T16:50:08+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-present-preclinical-data-highlighting-the-robust-anti-tumoral-activity-of-bt-001-oncolytic-virus-at-sitc-2021/</loc><lastmod>2026-07-09T15:47:09+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-business-update-and-q3-2021-financial-position/</loc><lastmod>2022-03-17T17:51:11+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-to-present-preclinical-data-on-bt-001-oncolytic-virus-at-sitc-2021/</loc><lastmod>2026-07-09T15:48:29+02:00</lastmod></url><url><loc>https://www.transgene.com/regulated-information/</loc><lastmod>2026-10-01T12:15:46+02:00</lastmod></url><url><loc>https://www.transgene.com/informations-financieres/</loc><lastmod>2025-12-15T16:04:18+01:00</lastmod></url><url><loc>https://www.transgene.com/information-boursiere/</loc><lastmod>2025-07-25T15:53:56+02:00</lastmod></url><url><loc>https://www.transgene.com/key-figures/</loc><lastmod>2026-03-24T17:49:50+01:00</lastmod></url><url><loc>https://www.transgene.com/information-generale-boursiere/</loc><lastmod>2026-04-01T08:34:40+02:00</lastmod></url><url><loc>https://www.transgene.com/analysts/</loc><lastmod>2025-12-09T17:17:34+01:00</lastmod></url><url><loc>https://www.transgene.com/evenements-et-presentations/</loc><lastmod>2025-03-26T23:13:42+01:00</lastmod></url><url><loc>https://www.transgene.com/assemblee-generale/</loc><lastmod>2026-05-22T16:14:59+02:00</lastmod></url><url><loc>https://www.transgene.com/annonce/</loc><lastmod>2021-11-22T16:58:04+01:00</lastmod></url><url><loc>https://www.transgene.com/annonce-substitut/</loc><lastmod>2021-11-22T11:57:15+01:00</lastmod></url><url><loc>https://www.transgene.com/annoncehome/</loc><lastmod>2022-06-10T14:49:03+02:00</lastmod></url><url><loc>https://www.transgene.com/tg405-fisrt-results/</loc><lastmod>2026-07-09T15:45:57+02:00</lastmod></url><url><loc>https://www.transgene.com/license-option-exercise-by-astrazeneca/</loc><lastmod>2026-07-09T15:45:00+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-financial-calendar-for-2022/</loc><lastmod>2026-07-09T15:44:32+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-persongen-announce-collaboration-to-evaluate-a-new-combination-therapy-against-solid-tumors/</loc><lastmod>2026-07-09T15:43:23+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-joint-jitc-publication-demonstrates-the-potential-of-bt-001-oncolytic-virus-to-provide-therapeutic-benefit-beyond-current-anti-pd1-anti-ctla-4-immune-checkpoint-blockade/</loc><lastmod>2026-07-09T15:42:42+02:00</lastmod></url><url><loc>https://www.transgene.com/ethics-and-compliance/</loc><lastmod>2025-10-07T14:37:26+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-appoints-steven-bloom-as-chief-business-officer/</loc><lastmod>2026-07-09T15:41:53+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-present-new-positive-preliminary-phase-i-data-on-tg4050-myvac-platform-its-individualized-therapeutic-cancer-vaccine-at-aacr-2022/</loc><lastmod>2026-07-09T15:40:31+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-announce-poster-presentation-on-bt-001-a-novel-antibody-encoding-oncolytic-virus-at-aacr-2022/</loc><lastmod>2026-07-09T15:41:16+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-confirms-the-potential-of-its-two-innovative-platforms-and-expects-significant-clinical-results-in-2022/</loc><lastmod>2026-07-09T15:39:46+02:00</lastmod></url><url><loc>https://www.transgene.com/transgenes-board-of-directors-strengthens-its-governance-and-proposes-the-appointment-of-dr-alessandro-riva-as-independent-chairman/</loc><lastmod>2026-07-09T15:38:29+02:00</lastmod></url><url><loc>https://www.transgene.com/availability-of-preparatory-documents-for-the-combined-general-meeting-of-may-25-2022/</loc><lastmod>2026-07-09T15:37:40+02:00</lastmod></url><url><loc>https://www.transgene.com/availability-of-transgenes-2021-universal-registration-document/</loc><lastmod>2026-07-09T15:31:36+02:00</lastmod></url><url><loc>https://www.transgene.com/phase-i-trials-of-personalized-cancer-vaccine-tg4050-in-surgically-treated-high-risk-head-and-neck-squamous-cell-carcinoma-hnscc-and-relapsing-ovarian-cancer-ovc-patients/</loc><lastmod>2026-01-06T01:02:28+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-present-new-positive-preliminary-phase-i-clinical-data-at-aacr-2022-reinforcing-the-potential-of-tg4050/</loc><lastmod>2026-07-09T15:33:54+02:00</lastmod></url><url><loc>https://www.transgene.com/phase-i-trials-of-personalized-cancer-vaccine-tg4050-in-surgically-treated-high-risk-head-and-neck-squamous-cell-carcinoma-hnscc-and-relapsing-ovarian-cancer-ovc-patients-2/</loc><lastmod>2023-08-31T10:55:08+02:00</lastmod></url><url><loc>https://www.transgene.com/pseudocowpox-virus-a-novel-vector-to-enhance-the-therapeutic-efficacy-of-antitumor-vaccination/</loc><lastmod>2025-11-12T16:03:06+01:00</lastmod></url><url><loc>https://www.transgene.com/all-of-transgenes-preclinical-and-clinical-assets-progressed-in-line-with-expectations-in-q1-2022/</loc><lastmod>2026-07-09T15:34:12+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-upcoming-investor-meetings-9/</loc><lastmod>2026-07-09T15:35:36+02:00</lastmod></url><url><loc>https://www.transgene.com/transgenes-combined-general-meeting-of-may-25-2022/</loc><lastmod>2026-07-09T15:30:25+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-present-updated-positive-preliminary-data-from-the-phase-i-clinical-trials-with-tg4050-myvac-platform-at-asco-2022/</loc><lastmod>2026-07-09T15:29:01+02:00</lastmod></url><url><loc>https://www.transgene.com/dr-alessandro-riva/</loc><lastmod>2026-01-29T17:16:17+01:00</lastmod></url><url><loc>https://www.transgene.com/prof-jean-yves-blay/</loc><lastmod>2025-10-13T16:51:34+02:00</lastmod></url><url><loc>https://www.transgene.com/carol-stuckley/</loc><lastmod>2025-12-17T09:12:24+01:00</lastmod></url><url><loc>https://www.transgene.com/phase-1-studies-of-personalized-neoantigen-vaccine-tg4050-in-ovarian-carcinoma-oc-and-head-and-heck-carcinoma-hnscc-2/</loc><lastmod>2026-01-06T01:01:06+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-presented-additional-phase-i-data-with-tg4050-myvac-platform-at-asco-2022/</loc><lastmod>2026-07-09T15:27:57+02:00</lastmod></url><url><loc>https://www.transgene.com/annonce-tg4050en/</loc><lastmod>2024-11-08T10:40:13+01:00</lastmod></url><url><loc>https://www.transgene.com/tg4050/</loc><lastmod>2026-09-08T12:18:57+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-announce-positive-progress-for-bt-001/</loc><lastmod>2026-07-09T15:27:07+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda/</loc><lastmod>2026-07-09T15:26:05+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-upcoming-investor-meetings-10/</loc><lastmod>2026-07-09T15:25:32+02:00</lastmod></url><url><loc>https://www.transgene.com/positive-readouts-for-transgenes-clinical-stage-candidates-generated-by-its-two-innovative-platforms-with-further-clinical-data-expected-in-the-second-half-of-2022/</loc><lastmod>2026-07-09T15:24:20+02:00</lastmod></url><url><loc>https://www.transgene.com/strongtransgene-confirms-the-potential-of-the-intravenous-routebrof-its-invir-io-oncolytic-viruses-against-solid-tumorsbrwith-tg6002-phase-i-data-presented-at-esmo-congressnbsp2022-strong/</loc><lastmod>2026-07-09T15:23:51+02:00</lastmod></url><url><loc>https://www.transgene.com/annoncehome-2/</loc><lastmod>2022-09-28T10:46:08+02:00</lastmod></url><url><loc>https://www.transgene.com/rd-day-presentations-to-highlight-transgenes-competitive-positioning-capabilities-to-engineer-novel-immunotherapies-for-patients-with-cancer-and-update-on-initial-clinical-data/</loc><lastmod>2026-07-09T15:22:14+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-positive-interim-analysis-results-of-phase-ii-trial-evaluating-tg4001-avelumab-vs-avelumab-in-hpv-positive-anogenital-cancers/</loc><lastmod>2026-07-09T15:21:41+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-business-update-and-q3-2022-financial-position/</loc><lastmod>2026-07-09T15:20:59+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022/</loc><lastmod>2026-07-09T15:20:10+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-upcoming-investor-meetings-11/</loc><lastmod>2026-07-09T15:18:53+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-financial-calendar-for-2023/</loc><lastmod>2026-07-09T15:18:15+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-receives-approval-to-start-a-phase-i-trial-of-tg6050-a-novel-il-12-armed-oncolytic-virus-given-by-intravenous-administration/</loc><lastmod>2026-07-09T15:17:53+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-appoints-john-c-bell-and-pedro-romero-as-key-scientific-advisors/</loc><lastmod>2026-07-09T15:13:23+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023/</loc><lastmod>2026-07-09T15:12:25+02:00</lastmod></url><url><loc>https://www.transgene.com/positive-data-on-key-clinical-candidates-delivered-in-2022-promising-outlook-for-2023-as-industry-interest-in-therapeutic-cancer-vaccines-and-oncolytic-viruses-gains-significant-momentum/</loc><lastmod>2026-07-09T15:11:11+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-upcoming-investor-meetings-12/</loc><lastmod>2026-07-09T15:10:39+02:00</lastmod></url><url><loc>https://www.transgene.com/john-bell/</loc><lastmod>2025-12-17T09:14:56+01:00</lastmod></url><url><loc>https://www.transgene.com/pedro-romero/</loc><lastmod>2025-04-30T15:29:31+02:00</lastmod></url><url><loc>https://www.transgene.com/scientific-advisors/</loc><lastmod>2026-03-23T16:58:30+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers/</loc><lastmod>2026-07-09T15:08:13+02:00</lastmod></url><url><loc>https://www.transgene.com/availability-of-transgenes-2022-universal-registration-document/</loc><lastmod>2026-07-09T15:06:14+02:00</lastmod></url><url><loc>https://www.transgene.com/annoncehome-2-3/</loc><lastmod>2023-04-06T22:53:55+02:00</lastmod></url><url><loc>https://www.transgene.com/availability-of-preparatory-documents-for-the-combined-general-meeting-of-may-5-2023/</loc><lastmod>2026-07-09T15:01:19+02:00</lastmod></url><url><loc>https://www.transgene.com/transgenes-board-of-directors-proposes-the-appointment-of-carol-stuckley-mba-as-new-independent-director/</loc><lastmod>2026-07-09T14:58:22+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-preclinical-results-showing-tg6050-a-novel-oncolytic-virus-induces-tumor-regression-by-activating-innate-and-adaptive-immune-responses-presented-at-aacr/</loc><lastmod>2026-07-09T14:57:30+02:00</lastmod></url><url><loc>https://www.transgene.com/tg6050-an-oncolytic-vaccinia-virus-armed-with-interleukin-12-and-anti-ctla4-antibody-induces-tme-remodeling-and-strong-anti-tumoral-responses2/</loc><lastmod>2025-12-17T10:54:23+01:00</lastmod></url><url><loc>https://www.transgene.com/extracellular-vesicles-ev-mediators-of-therapeutic-vaccination-in-vivo-and-in-vitro-characterization-of-evs-generated-after-infection-of-human-and-murine-cells-with-therapeutic-poxviruses-2/</loc><lastmod>2025-11-12T16:01:39+01:00</lastmod></url><url><loc>https://www.transgene.com/advanced-patient-derived-lung-tumoroids-to-identify-limiting-factors-for-oncolytic-virotherapy/</loc><lastmod>2025-11-12T15:38:51+01:00</lastmod></url><url><loc>https://www.transgene.com/feasibility-and-immunogenicity-of-adjuvant-tg4050-a-patient-tailored-cancer-vaccine-in-head-and-neck-and-ovarian-cancer/</loc><lastmod>2023-04-16T19:51:00+02:00</lastmod></url><url><loc>https://www.transgene.com/advanced-patient-derived-lung-tumoroids-to-identify-limiting-factors-for-oncolytic-virotherapy-2/</loc><lastmod>2023-04-16T20:18:44+02:00</lastmod></url><url><loc>https://www.transgene.com/poxstg-a-novel-chimeric-poxvirus-with-improved-oncolytic-potency/</loc><lastmod>2025-11-12T15:39:06+01:00</lastmod></url><url><loc>https://www.transgene.com/new-data-showing-that-transgene-and-necs-individualized-cancer-vaccine-tg4050-induces-strong-and-specific-immune-responses-against-tumors-presented-at-aacr-2023/</loc><lastmod>2026-07-09T14:56:38+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-new-leadership-structure-to-accelerate-the-development-of-its-innovative-immunotherapy-portfolio/</loc><lastmod>2026-07-09T14:56:09+02:00</lastmod></url><url><loc>https://www.transgene.com/transgenes-combined-general-meeting-of-may-5-2023/</loc><lastmod>2026-07-09T14:55:14+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-first-patient-dosed-in-phase-i-trial-evaluating-tg6050-a-novel-il-12-armed-oncolytic-virus-administrated-intravenously-in-non-small-cell-lung-cancer/</loc><lastmod>2026-07-09T14:54:38+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-provides-business-update-and-q1-2023-financial-position/</loc><lastmod>2026-07-09T14:52:34+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-report-positive-phase-ia-data-on-oncolytic-virus-bt-001-in-solid-tumors/</loc><lastmod>2026-07-09T14:52:00+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-present-data-on-its-two-therapeutic-cancer-vaccins-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting/</loc><lastmod>2026-07-09T14:51:11+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-presents-immunological-data-demonstrating-that-tg4001-a-novel-therapeutic-cancer-vaccine-can-induce-t-cell-responses-against-hpv16-antigens-in-the-ongoing-phase-ii-trial-at-asco-2023/</loc><lastmod>2026-07-09T14:50:19+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-nec-present-new-data-on-tg4050-an-individualized-cancer-vaccine-showing-it-induces-specific-immune-responses-against-head-and-neck-carcinoma-at-asco-2023/</loc><lastmod>2026-07-09T14:49:34+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-receives-15-3-million-from-the-sale-of-securities-held-for-sale/</loc><lastmod>2026-07-09T14:48:43+02:00</lastmod></url><url><loc>https://www.transgene.com/phase-ib-ii-trial-of-tipapkinogene-sovacivec-tg4001-a-therapeutic-human-papillomavirus-16-vaccine-in-combination-with-avelumab-in-patients-with-advanced-human-papillomavirus-16-positive-cancers/</loc><lastmod>2025-12-17T10:53:47+01:00</lastmod></url><url><loc>https://www.transgene.com/safety-and-immunogenicity-of-tg4050-a-personalized-cancer-vaccine-in-head-and-neck-carcinoma/</loc><lastmod>2025-12-17T10:54:01+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-upcoming-investor-meetings-13/</loc><lastmod>2026-07-09T14:48:18+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-advances-its-innovative-immunotherapy-pipeline-and-extends-financial-visibility-until-the-end-of-2024/</loc><lastmod>2026-07-09T14:46:42+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-first-patient-treated-in-part-b-of-phase-i-trial-assessing-the-novel-oncolytic-virus-bt-001-in-combination-with-keytrudapembrolizumab/</loc><lastmod>2026-07-09T14:45:58+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-business-update-and-q3-2023-financial-position/</loc><lastmod>2026-07-09T14:45:17+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-strengthens-its-leadership-team-to-accelerate-its-growth-strategy/</loc><lastmod>2026-07-09T14:44:25+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-upcoming-investor-meetings-14/</loc><lastmod>2026-07-09T14:43:19+02:00</lastmod></url><url><loc>https://www.transgene.com/lucie-larguier2/</loc><lastmod>2025-07-23T16:32:59+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-nec-extend-their-collaboration-to-continue-joint-clinical-development-of-neoantigen-cancer-vaccine-tg4050/</loc><lastmod>2026-07-09T14:42:03+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-financial-calendar-for-2024/</loc><lastmod>2026-07-09T14:41:13+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-further-strengthens-management-team-with-appointment-of-james-wentworth-as-chief-business-officer/</loc><lastmod>2026-07-09T14:40:21+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-nec-and-bostongene-expand-collaboration-for-phase-i-ii-clinical-trial-of-neoantigen-cancer-vaccine-tg4050/</loc><lastmod>2026-07-09T14:38:56+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-present-new-data-on-tg4050-an-individualized-cancer-vaccine-at-aacr-2024/</loc><lastmod>2026-07-09T14:37:50+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-upcoming-investor-meetings-15/</loc><lastmod>2026-07-09T14:37:17+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-appoints-lucie-larguier-as-chief-financial-officer-and-christelle-schwoerer-as-chief-human-resources-officer/</loc><lastmod>2026-07-09T14:35:44+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-anticipates-significant-progress-from-immunotherapy-pipeline-in-2024-and-extends-financial-visibility-until-q4-2025/</loc><lastmod>2026-07-09T14:36:33+02:00</lastmod></url><url><loc>https://www.transgene.com/personalized-vaccine-tg4050-induces-polyepitopic-immune-responses-against-private-neoantigens-in-resected-hpv-negative-head-and-neck-cancers-2/</loc><lastmod>2025-12-17T10:53:31+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-nec-present-first-clinical-benefits-of-neoantigen-cancer-vaccine-tg4050-in-head-neck-cancer-at-aacr-2024-2/</loc><lastmod>2026-07-09T14:34:31+02:00</lastmod></url><url><loc>https://www.transgene.com/availability-of-transgenes-2023-universal-registration-document/</loc><lastmod>2026-07-09T14:34:01+02:00</lastmod></url><url><loc>https://www.transgene.com/availability-of-of-preparatory-documents-for-the-combined-general-meeting-of-may-15-2024/</loc><lastmod>2026-07-09T14:33:12+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-provides-business-and-financial-update-for-q1-2024/</loc><lastmod>2026-07-09T14:32:14+02:00</lastmod></url><url><loc>https://www.transgene.com/transgenes-combined-general-meeting-of-may-15-2024-2/</loc><lastmod>2026-07-09T14:31:25+02:00</lastmod></url><url><loc>https://www.transgene.com/michel-baguenault/</loc><lastmod>2025-12-19T15:49:54+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-first-patient-enrolled-in-phase-ii-part-of-randomized-phase-i-ii-trial-evaluating-lead-cancer-vaccine-tg4050-in-head-and-neck-cancer/</loc><lastmod>2026-07-09T14:30:29+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-to-present-poster-on-oncolytic-virus-bt-001-at-esmo-2024/</loc><lastmod>2026-07-09T14:29:34+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-strengthens-its-balance-sheet-via-equity-conversion-of-current-account-advance-from-tsgh-2/</loc><lastmod>2026-07-09T14:28:23+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-preclinical-proof-of-concept-data-of-oncolytic-virus-tg6050-published-in-jitc/</loc><lastmod>2026-07-09T14:27:24+02:00</lastmod></url><url><loc>https://www.transgene.com/tg6050-an-oncolytic-vaccinia-virus-encoding-interleukin-12-and-anti-ctla-4-antibody-favors-tumor-regression-via-profound-immune-remodeling-of-the-tumor-microenvironment/</loc><lastmod>2025-12-17T10:53:16+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-participate-in-htid-conference-and-investor-access-forum-in-paris/</loc><lastmod>2026-07-09T14:26:26+02:00</lastmod></url><url><loc>https://www.transgene.com/initial-clinical-results-of-bt-001-an-oncolytic-virus-expressing-an-anti-ctla4-mab-administered-as-single-agent-and-in-combination-with-pembrolizumab-in-patients-with-advanced-solid-tumors/</loc><lastmod>2025-11-12T15:10:06+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-to-present-promising-initial-phase-i-iia-data-on-oncolytic-virus-bt-001-at-esmo-2024/</loc><lastmod>2026-07-09T14:25:33+02:00</lastmod></url><url><loc>https://www.transgene.com/tg6050-an-oncolytic-vaccinia-virus-encoding-interleukin-12-and-anti-ctla-4-antibody-favors-tumor-regression-via-profound-immune-remodeling-of-the-tumor-microenvionment/</loc><lastmod>2025-12-17T10:53:04+01:00</lastmod></url><url><loc>https://www.transgene.com/maurizio-ceppi-phd/</loc><lastmod>2025-12-17T08:52:03+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-appoints-two-seasoned-leaders-in-oncology-to-drive-its-next-phase-of-innovation/</loc><lastmod>2026-07-09T14:24:32+02:00</lastmod></url><url><loc>https://www.transgene.com/emmanuelle-dochy-md/</loc><lastmod>2025-12-15T22:09:52+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvents-oncolytic-virus-bt-001-shows-promising-antitumor-activity-in-ongoing-phase-i-iia-trial-in-solid-tumors-that-failed-previous-treatment/</loc><lastmod>2026-07-09T14:23:27+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-report-major-clinical-data-before-the-end-of-2024-confirmed-financial-visibility-until-q4-2025/</loc><lastmod>2026-07-09T14:22:42+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-present-a-poster-on-updated-data-for-tg4050-at-sitc-2024/</loc><lastmod>2026-07-09T14:21:48+02:00</lastmod></url><url><loc>https://www.transgene.com/randomized-phase-i-trial-of-adjuvant-individualized-tg4050-vaccine-in-patients-with-locally-advanced-resected-hpv-negative-head-and-neck-squamous-cell-carcinoma-hnscc/</loc><lastmod>2025-10-22T09:45:31+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-provides-update-on-phase-ii-trial-of-therapeutic-cancer-vaccine-tg4001-in-recurrent-or-metastatic-hpv16-positive-cervical-and-anogenital-cancers/</loc><lastmod>2026-07-09T14:21:08+02:00</lastmod></url><url><loc>https://www.transgene.com/tg7010-a-novel-chimeric-oncolytic-poxvirus-encoding-il-12-with-improved-properties-for-systemic-delivery/</loc><lastmod>2025-11-12T15:36:44+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-nec-present-new-data-confirming-clinical-proof-of-principle-for-neoantigen-cancer-vaccine-tg4050-in-head-neck-cancer-at-sitc-2024/</loc><lastmod>2026-07-09T14:17:58+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-probiogen-join-forces-to-advance-individualized-cancer-vaccine-develpment/</loc><lastmod>2026-07-09T14:20:23+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-business-pipeline-and-financial-update-for-q3-2024/</loc><lastmod>2026-07-09T14:19:08+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-financial-calendar-for-2025/</loc><lastmod>2026-07-09T14:17:15+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-participate-in-the-biomed-forum-investor-conference/</loc><lastmod>2026-07-09T14:16:26+02:00</lastmod></url><url><loc>https://www.transgene.com/financial-reports-2025/</loc><lastmod>2026-11-10T10:17:24+01:00</lastmod></url><url><loc>https://www.transgene.com/corporate-governance-3/</loc><lastmod>2026-01-07T11:53:53+01:00</lastmod></url><url><loc>https://www.transgene.com/cg-board-of-directors/</loc><lastmod>2025-12-09T15:53:36+01:00</lastmod></url><url><loc>https://www.transgene.com/cg-management-committee/</loc><lastmod>2025-04-03T19:23:41+02:00</lastmod></url><url><loc>https://www.transgene.com/cg-governance-and-internal-procedures/</loc><lastmod>2025-10-06T17:34:12+02:00</lastmod></url><url><loc>https://www.transgene.com/simone-steiner/</loc><lastmod>2026-03-06T08:27:40+01:00</lastmod></url><url><loc>https://www.transgene.com/our-leadership/</loc><lastmod>2026-09-25T09:17:41+02:00</lastmod></url><url><loc>https://www.transgene.com/svg-pipeline/</loc><lastmod>2025-04-24T16:52:40+02:00</lastmod></url><url><loc>https://www.transgene.com/teaser-produits-tg4070/</loc><lastmod>2026-07-07T14:17:42+02:00</lastmod></url><url><loc>https://www.transgene.com/teaser-produits-placeholder/</loc><lastmod>2025-05-15T13:03:15+02:00</lastmod></url><url><loc>https://www.transgene.com/teaser-tg-mva/</loc><lastmod>2026-07-07T14:02:24+02:00</lastmod></url><url><loc>https://www.transgene.com/teaser-produits-research-innovation/</loc><lastmod>2026-07-03T09:32:40+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-shares-euronext-paris-tng-eligible-for-inclusion-in-pea-pme-accounts/</loc><lastmod>2026-07-09T14:15:39+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-participate-in-upcoming-investor-meetings/</loc><lastmod>2026-07-09T14:14:48+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-achieves-key-milestones-in-2024-including-clinical-proof-of-principle-for-individualized-cancer-vaccine-strong-outlook-for-2025/</loc><lastmod>2026-07-09T14:13:49+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-appoints-chief-technical-officer-cto-to-power-future-innovations/</loc><lastmod>2026-07-09T13:40:48+02:00</lastmod></url><url><loc>https://www.transgene.com/availability-of-transgenes-2024-universal-registration-document-urd/</loc><lastmod>2026-07-09T13:39:49+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-provide-updated-phase-i-data-in-a-rapid-oral-presentation-on-individualized-therapeutic-cancer-vaccine-tg4050-at-asco-2025/</loc><lastmod>2026-07-09T13:38:50+02:00</lastmod></url><url><loc>https://www.transgene.com/availability-of-preparatory-documents-for-the-combined-general-meeting-of-may-15-2025/</loc><lastmod>2026-07-09T13:37:46+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-provides-business-and-financial-update-for-q1-2025/</loc><lastmod>2026-07-09T13:36:53+02:00</lastmod></url><url><loc>https://www.transgene.com/credits/</loc><lastmod>2025-05-07T12:09:33+02:00</lastmod></url><url><loc>https://www.transgene.com/fatima-cardoso/</loc><lastmod>2025-07-22T16:36:59+02:00</lastmod></url><url><loc>https://www.transgene.com/antoine-italiano/</loc><lastmod>2026-01-22T16:02:48+01:00</lastmod></url><url><loc>https://www.transgene.com/ignacio-melero/</loc><lastmod>2025-10-13T18:40:49+02:00</lastmod></url><url><loc>https://www.transgene.com/sabine-tejpar/</loc><lastmod>2025-07-22T16:41:06+02:00</lastmod></url><url><loc>https://www.transgene.com/management-committee-2/</loc><lastmod>2025-07-23T17:40:07+02:00</lastmod></url><url><loc>https://www.transgene.com/onglet-cp/</loc><lastmod>2025-10-14T11:19:36+02:00</lastmod></url><url><loc>https://www.transgene.com/transgenes-combined-general-meeting-of-may-15-2025/</loc><lastmod>2026-07-09T13:36:22+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-nec-present-durable-disease-free-survival-and-sustained-t-cell-responses-at-24-months-with-individualized-cancer-vaccine-tg4050/</loc><lastmod>2026-07-09T13:34:53+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-present-24-month-disease-free-survival-data-from-all-patients-in-phase-i-part-of-trial-of-individualized-cancer-vaccine-tg4050-at-asco-2025/</loc><lastmod>2026-07-09T13:32:59+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-host-webcast-on-positive-tg4050-head-and-neck-cancer-data-presented-at-asco-2025/</loc><lastmod>2025-10-16T17:20:31+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-participate-in-upcoming-meetings-with-biotech-industry-leaders/</loc><lastmod>2025-10-07T14:29:27+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-completes-initial-patient-screening-in-phase-ii-part-of-tg4050-trial-in-operable-head-and-neck-cancer/</loc><lastmod>2026-07-09T13:30:56+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-appoints-seasoned-industry-executive-emmanuelle-quiles-to-board-of-directors-as-independant-director/</loc><lastmod>2025-10-06T18:05:58+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-to-present-updated-data-on-armed-oncolytic-virus-bt-001-at-esmo-2025/</loc><lastmod>2026-07-09T13:29:33+02:00</lastmod></url><url><loc>https://www.transgene.com/transgenes-individualized-neoantigen-therapeutic-cancer-vaccine-tg4050-delivers-positive-randomized-phase-i-data-randomization-to-be-completed-in-phase-ii-part-in-q4-2025/</loc><lastmod>2026-07-09T13:28:30+02:00</lastmod></url><url><loc>https://www.transgene.com/randomized-phase-ii-trial-evaluating-the-combination-of-tg4001-a-hpv16-therapeutic-vaccineand-avelumab-ave-in-patients-pts-with-immunotherapy-naive-recurrent-and-or-metastaticr-m-hpv16-positive/</loc><lastmod>2025-11-17T16:33:30+01:00</lastmod></url><url><loc>https://www.transgene.com/randomized-phase-i-trial-of-adjuvant-personalized-cancer-vaccine-tg4050-in-resected-locally-advanced-la-head-and-neck-squamous-cell-carcinoma-hnsccpatients-pts/</loc><lastmod>2026-01-08T12:20:31+01:00</lastmod></url><url><loc>https://www.transgene.com/a-phase-i-clinical-trial-of-intrahepatic-artery-delivery-of-tg6002-in-combination-with-oral-5-fluorocytosine-in-patients-with-liver-dominant-metastatic-colorectal-cancer/</loc><lastmod>2026-01-06T08:54:02+01:00</lastmod></url><url><loc>https://www.transgene.com/utilisation-de-lanalyseur-xcelligence-rtca-esight-pour-levaluation-de-la-nouvelle-plateforme-de-virus-oncolytique-de-transgene/</loc><lastmod>2025-11-12T15:58:16+01:00</lastmod></url><url><loc>https://www.transgene.com/prof-ottensmeiers-point-of-view/</loc><lastmod>2025-10-14T17:06:45+02:00</lastmod></url><url><loc>https://www.transgene.com/transgenes-individualized-neoantigen-therapeutic-cancer-vaccine-tg4050-delivers-positive-randomized-phase-i-data-randomization-to-be-completed-in-phase-ii-part-in-q4-2025-2/</loc><lastmod>2025-10-07T14:09:47+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-nec-present-durable-disease-free-survival-and-sustained-t-cell-responses-at-24-months-with-individualized-cancer-vaccin-tg4050/</loc><lastmod>2025-10-07T14:18:51+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-present-new-immunological-data-from-phase-i-trial-of-individualized-therapeutic-cancer-vaccine-tg4050-at-sitc-2025/</loc><lastmod>2025-10-16T17:40:49+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvent-to-present-translational-data-and-updated-clinical-results-on-armed-oncolytic-virus-bt-001-at-esmo-2025/</loc><lastmod>2025-11-12T15:06:54+01:00</lastmod></url><url><loc>https://www.transgene.com/updated-clinical-results-of-bt-001-an-oncolytic-virus-expressing-an-anti-ctla4-mabadministered-in-combination-with-pembrolizumab-in-patients-with-advanced-solid-tumors/</loc><lastmod>2025-12-17T10:47:50+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-bioinvents-armed-oncolytic-virus-bt-001-shows-positive-local-abscopal-and-sustained-antitumoral-activity-in-advanced-refractory-tumors/</loc><lastmod>2025-11-12T15:06:34+01:00</lastmod></url><url><loc>https://www.transgene.com/pooled-safety-analysis-of-modified-vaccinia-virus-ankara-based-therapeutic-vaccine-alone-or-in-combination-in-cancer-and-cervical-intraepithelial-neoplasia-cin-clinical-trials/</loc><lastmod>2025-11-12T15:57:46+01:00</lastmod></url><url><loc>https://www.transgene.com/vacdesignr-a-tool-for-optimizing-recombinant-poxvirus-vaccine-production/</loc><lastmod>2025-12-17T10:47:17+01:00</lastmod></url><url><loc>https://www.transgene.com/profiling-of-the-neoantigen-specific-t-cell-response-after-adjuvant-tg4050-individualized-therapeutic-vaccination-in-a-randomized-phase-i-trial-for-locally-advanced-resected-hpv-negative-hnscc/</loc><lastmod>2025-12-17T10:47:36+01:00</lastmod></url><url><loc>https://www.transgene.com/a-pseudocowpox-virus-vector-to-generate-human-b-cell-based-vaccines-2/</loc><lastmod>2025-11-17T14:37:19+01:00</lastmod></url><url><loc>https://www.transgene.com/tg6002-oncolytic-vaccinia-virusand-chemotherapy-synergy-apromising-strategy-for-pancreaticductal-adenocarcinoma/</loc><lastmod>2026-01-06T09:12:47+01:00</lastmod></url><url><loc>https://www.transgene.com/oncolytic-virus-tg6002-safety-and-activity-after-intrahepatic-artery-administration-in-patients-with-liver-dominant-metastatic-colorectal-cancer/</loc><lastmod>2025-11-17T16:28:14+01:00</lastmod></url><url><loc>https://www.transgene.com/immunogenicity-and-clinical-activity-of-tipapkinogen-sovacivec-tg4001-an-hpv-16-cancervaccine-a-randomized-phase-2-study-in-recurrent-or-metastatic-r-m-anogenital-cancers/</loc><lastmod>2026-02-03T13:50:32+01:00</lastmod></url><url><loc>https://www.transgene.com/a-randomized-phase-ii-trial-of-tg4001-plus-avelumab-versus-avelumab-alone-in-recurrent-metastatic-r-m-human-papilloma-virus-hpv-16-positive-anogenital-cancers/</loc><lastmod>2025-11-17T16:36:57+01:00</lastmod></url><url><loc>https://www.transgene.com/updated-data-of-biodistribution-and-activity-of-oncolytic-virus-tg6002-after-intravenous-administrationin-patients-with-advanced-gastrointestinal-carcinomas/</loc><lastmod>2026-01-06T13:07:53+01:00</lastmod></url><url><loc>https://www.transgene.com/comprehensive-preclinical-studies-of-bt-001-an-oncolytic-vaccinia-virus-armed-with-treg-depleting-ctla4-and-gm-csf/</loc><lastmod>2025-11-17T16:58:14+01:00</lastmod></url><url><loc>https://www.transgene.com/vectorized-treg-depleting-%ce%b1ctla-4-elicits-antigen-cross-presentation-and-cd8-t-cell-immunity-to-reject-cold-tumors/</loc><lastmod>2025-11-17T17:03:57+01:00</lastmod></url><url><loc>https://www.transgene.com/preclinical-evaluation-of-the-oncolytic-vaccinia-virus-tg6002-by-translational-research-on-canine-breast-cancer/</loc><lastmod>2026-01-06T15:25:30+01:00</lastmod></url><url><loc>https://www.transgene.com/teaser-produits-tg6050/</loc><lastmod>2025-12-17T10:39:26+01:00</lastmod></url><url><loc>https://www.transgene.com/tg6050/</loc><lastmod>2026-03-23T16:48:23+01:00</lastmod></url><url><loc>https://www.transgene.com/tg4050-at-2025-sitc-new-ph-i-immunological-data/</loc><lastmod>2025-12-22T09:49:50+01:00</lastmod></url><url><loc>https://www.transgene.com/announces-the-temporary-suspension-of-trading-of-its-shares-on-euronext-paris/</loc><lastmod>2026-07-09T13:24:35+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-the-resume-of-trading-of-its-shares-on-euronext-paris-as-of-the-opening-of-the-markets/</loc><lastmod>2026-07-09T13:10:31+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-participate-in-upcoming-investor-meetings-2/</loc><lastmod>2026-07-09T13:09:22+02:00</lastmod></url><url><loc>https://www.transgene.com/vectorization-in-an-oncolytic-vaccinia-virus-of-an-antibody-a-fab-and-a-scfv-against-programmed-cell-death-1-pd-1-allow-their-intratumoral-delivery-and-an-improved-tumor-growth-inhibition-2/</loc><lastmod>2026-01-05T19:27:46+01:00</lastmod></url><url><loc>https://www.transgene.com/oncolytic-vaccinia-virus-tg6002-demonstrates-potent-efficiency-in-pancreatic-tumor-alone-and-in-combination-with-standard-chemotherapies/</loc><lastmod>2026-01-06T09:21:02+01:00</lastmod></url><url><loc>https://www.transgene.com/vectorization-in-an-oncolytic-vaccinia-virus-of-an-antibody-a-fab-and-a-scfv-against-programmed-cell-death-1-pd-1-allow-their-intratumoral-delivery-and-an-improved-tumor-growth-inhibition-3/</loc><lastmod>2026-01-05T19:43:23+01:00</lastmod></url><url><loc>https://www.transgene.com/engineering-oncolytic-vaccinia-virus-with-improved-cancer-killing-abilities/</loc><lastmod>2026-01-06T15:47:49+01:00</lastmod></url><url><loc>https://www.transgene.com/vectorized-gene-therapy-of-liver-tumors-proof-of-concept-of-tg4023-mva-fcu1-in-combination-with-flucytosine/</loc><lastmod>2026-01-06T00:34:36+01:00</lastmod></url><url><loc>https://www.transgene.com/local-and-abscopal-effects-in-oncolytic-virotherapy-are-boosted-by-immune-checkpoint-blockade-immunogenic-chemotherapy-or-ifnar-blockade/</loc><lastmod>2026-01-06T09:49:52+01:00</lastmod></url><url><loc>https://www.transgene.com/tg6002-a-novel-oncolytic-and-vectorized-gene-pro-drug-therapy-approach-to-treat-glioblastoma/</loc><lastmod>2026-01-06T09:19:27+01:00</lastmod></url><url><loc>https://www.transgene.com/immune-checkpoint-blockade-immunogenic-chemotherapy-or-ifn-%ce%b1-blockade-boost-the-local-and-abscopal-effects-of-oncolytic-virotherapy/</loc><lastmod>2026-01-06T15:55:04+01:00</lastmod></url><url><loc>https://www.transgene.com/tg6002-a-novel-oncolytic-and-vectorized-gene-pro-drug-therapy-approach-to-treat-glioblastoma-2/</loc><lastmod>2026-01-06T09:20:33+01:00</lastmod></url><url><loc>https://www.transgene.com/antibody-armed-oncolytic-vaccinia-virus-to-block-immunosuppressive-pathways-in-the-tumor-microenvironment/</loc><lastmod>2026-01-05T20:26:00+01:00</lastmod></url><url><loc>https://www.transgene.com/the-enhanced-tumor-specificity-of-tg6002-an-armed-oncolytic-vaccinia-virus-deleted-in-two-genes-involved-in-nucleotide-metabolism/</loc><lastmod>2026-01-06T09:18:09+01:00</lastmod></url><url><loc>https://www.transgene.com/the-efficacy-and-safety-of-tipapkinogen-sovacivec-tg4001-therapeutic-hpv-vaccine-in-cervical-intraepithelial-neoplasia-grades-2-and-3-randomized-controlled-phase-ii-trial-with-2-5-years-of-follow-u/</loc><lastmod>2026-01-05T20:34:43+01:00</lastmod></url><url><loc>https://www.transgene.com/phase-ib-ii-trial-of-tg4001-tipapkinogene-sovacivec-a-therapeutic-hpv-vaccine-and-avelumab-in-patients-with-recurrent-metastatic-hpv16-positive-cancers/</loc><lastmod>2026-01-05T20:40:54+01:00</lastmod></url><url><loc>https://www.transgene.com/meta-analysis-of-two-phase-1b-randomized-double-blind-placebo-controlled-clinical-trials-of-the-hbv-therapeutic-vaccines-tg1050-and-t101-developed-in-europe-canada-or-china-2/</loc><lastmod>2026-01-06T09:47:37+01:00</lastmod></url><url><loc>https://www.transgene.com/oncolytic-vaccinia-virus-contains-a-potent-cd80-cd86-ligand-whose-deletion-confers-higher-tolerance-and-potential-synergy-with-immune-arming/</loc><lastmod>2026-01-05T20:59:06+01:00</lastmod></url><url><loc>https://www.transgene.com/bt-001-an-oncolytic-vaccinia-virus-armed-with-a-treg-depletion-optimized-recombinant-human-anti-ctla4-antibody-and-gm-csf-to-target-the-tumor-microenvironment/</loc><lastmod>2026-01-06T01:06:19+01:00</lastmod></url><url><loc>https://www.transgene.com/design-of-an-innovative-model-to-improve-anticancer-therapeutic-treatment-based-on-a-vascularized-3d-organoids-derived-from-patients-lung-tumors-for-the-purpose-of-precision-medicine-2/</loc><lastmod>2026-01-05T22:06:15+01:00</lastmod></url><url><loc>https://www.transgene.com/bt-001-an-oncolytic-vaccinia-virus-armed-with-a-treg-depletion-optimized-recombinant-human-anti-ctla4-antibody-and-gm-csf-to-target-the-tumor-microenvironment-2/</loc><lastmod>2026-01-06T01:06:05+01:00</lastmod></url><url><loc>https://www.transgene.com/non-clinical-and-clinical-safety-of-mva-based-immunotherapy-products-targeting-cancer-and-infectious-diseases-2/</loc><lastmod>2026-01-06T00:40:51+01:00</lastmod></url><url><loc>https://www.transgene.com/bt-001-an-oncolytic-vaccinia-virus-armed-with-a-treg-depletion-optimized-recombinant-human-anti-ctla4-antibody-and-gm-csf-to-target-the-tumor-microenvironment-3/</loc><lastmod>2026-01-05T22:33:12+01:00</lastmod></url><url><loc>https://www.transgene.com/bt-001-an-oncolytic-vaccinia-virus-armed-with-a-treg-depletion-optimized-recombinant-human-anti-ctla4-antibody-and-gm-csf-to-target-the-tumor-microenvironment-4/</loc><lastmod>2026-01-05T22:38:43+01:00</lastmod></url><url><loc>https://www.transgene.com/bt-001-an-oncolytic-vaccinia-virus-armed-with-a-treg-depletion-optimized-recombinant-human-anti-ctla4-antibody-and-gm-csf-to-target-the-tumor-microenvironment-5/</loc><lastmod>2026-01-05T22:44:47+01:00</lastmod></url><url><loc>https://www.transgene.com/safety-studies-and-viral-shedding-of-intramuscular-administration-of-oncolytic-vaccinia-virus-tg6002-in-healthy-beagle-dogs/</loc><lastmod>2026-01-06T09:17:47+01:00</lastmod></url><url><loc>https://www.transgene.com/tg4001-tipapkinogene-sovacivec-and-avelumab-for-recurrent-metastatic-r-m-human-papilloma-virus-hpv-16-cancers-clinical-efficacy-and-immunogenicity/</loc><lastmod>2026-01-06T01:03:46+01:00</lastmod></url><url><loc>https://www.transgene.com/high-oncolytic-activity-of-a-double-deleted-vaccinia-virus-copenhagen-strain-against-malignant-pleural-mesothelioma-2/</loc><lastmod>2026-01-06T11:26:16+01:00</lastmod></url><url><loc>https://www.transgene.com/tg4001-tipapkinogene-sovacivec-and-avelumab-for-recurrent-metastatic-r-m-human-papilloma-virus-hpv-16-cancers-clinical-efficacy-and-immunogenicity-2/</loc><lastmod>2026-01-06T01:03:30+01:00</lastmod></url><url><loc>https://www.transgene.com/fluorescent-tagged-vaccinia-virus-genome-allows-rapid-and-efficient-measurement-of-oncolytic-potential-and-discovery-of-oncolytic-modulators-2/</loc><lastmod>2026-01-06T00:21:31+01:00</lastmod></url><url><loc>https://www.transgene.com/safety-biodistribution-and-viral-shedding-of-oncolytic-vaccinia-virus-tg6002-administered-intravenously-in-healthy-beagle-dogs/</loc><lastmod>2026-01-05T23:29:21+01:00</lastmod></url><url><loc>https://www.transgene.com/safety-biodistribution-and-viral-shedding-of-oncolytic-vaccinia-virus-tg6002-administered-intravenously-in-healthy-beagle-dogs-2/</loc><lastmod>2026-01-06T09:17:13+01:00</lastmod></url><url><loc>https://www.transgene.com/oncolytic-virus-tg6002-locates-to-tumors-after-intravenous-infusion-and-induces-tumor-specific-expression-of-a-functional-pro-drug-activating-enzyme-in-patients-with-advanced-gastrointestinal-carcinom/</loc><lastmod>2026-01-06T13:17:32+01:00</lastmod></url><url><loc>https://www.transgene.com/3d-organoids-derived-from-patients-lung-tumors-a-tool-for-investigating-the-potential-of-oncolytic-viruses/</loc><lastmod>2026-01-06T08:54:33+01:00</lastmod></url><url><loc>https://www.transgene.com/bioavailability-and-activity-of-oncolytic-virus-tg6002-after-intravenous-administration-in-patients-with-advanced-gastrointestinal-carcinomas/</loc><lastmod>2026-01-06T13:16:04+01:00</lastmod></url><url><loc>https://www.transgene.com/phase-ib-ii-trial-of-tipapkinogene-sovacivec-tg4001-a-therapeutic-human-papillomavirus-16-vaccine-in-combination-with-avelumab-in-patients-with-advanced-human-papillomavirus-16-positive-cancers-2/</loc><lastmod>2026-01-06T10:20:48+01:00</lastmod></url><url><loc>https://www.transgene.com/search/</loc><lastmod>2026-01-06T12:36:27+01:00</lastmod></url><url><loc>https://www.transgene.com/the-efficacy-and-safety-of-tipapkinogen-sovacivec-tg4001-therapeutic-hpv-vaccine-in-cervical-intraepithelial-neoplasia-grades-2-and-3-randomized-controlled-phase-ii-trial-with-2-5-years-of-follow-u-2/</loc><lastmod>2026-01-06T15:35:26+01:00</lastmod></url><url><loc>https://www.transgene.com/phase-ib-ii-trial-of-tg4001-tipapkinogene-sovacivec-a-therapeutic-hpv-vaccine-and-avelumab-in-patients-with-recurrent-metastatic-hpv16-positive-cancers-2/</loc><lastmod>2026-01-07T11:13:54+01:00</lastmod></url><url><loc>https://www.transgene.com/vectorization-in-an-oncolytic-vaccinia-virus-of-an-antibody-a-fab-and-a-scfv-against-programmed-cell-death-1-pd-1-allow-their-intratumoral-delivery-and-an-improved-tumor-growth-inhibition-4/</loc><lastmod>2026-01-06T15:45:46+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-the-success-of-its-capital-increase/</loc><lastmod>2026-07-09T13:22:31+02:00</lastmod></url><url><loc>https://www.transgene.com/contribution-of-yeast-to-synthetic-virology/</loc><lastmod>2026-01-08T12:56:06+01:00</lastmod></url><url><loc>https://www.transgene.com/colorectal-cancer-hepatic-metastasis-modeling-by-advanced-3d-bioprinting-allows-demonstration-of-oncolytic-viral-chemotherapeutic-delivery/</loc><lastmod>2026-01-08T12:54:32+01:00</lastmod></url><url><loc>https://www.transgene.com/viral-based-individualized-neoantigen-vaccine-as-adjuvant-treatment-in-resected-head-and-neck-squamous-cell-carcinoma-immunogenicity-and-efficacy-from-a-randomized-phase-i-trial/</loc><lastmod>2026-01-08T19:05:29+01:00</lastmod></url><url><loc>https://www.transgene.com/nature-communications/</loc><lastmod>2026-09-02T18:06:43+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-publishes-phase-i-data-supporting-tg4050s-potential-in-preventing-head-and-neck-cancer-relapse/</loc><lastmod>2026-07-09T13:08:48+02:00</lastmod></url><url><loc>https://www.transgene.com/oncolytic-viruses-alter-the-biogenesis-of-tumor-extracellular-vesicles-and-influence-their-immunogenicity/</loc><lastmod>2026-01-13T16:00:10+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-further-strengthens-scientific-advisory-board-with-appointments-of-renowned-cancer-immunotherapy-experts-antoine-italiano-and-ignacio-melero/</loc><lastmod>2026-01-22T15:47:15+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-announces-financial-calendar-for-2026/</loc><lastmod>2026-07-09T13:07:31+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-showcase-potential-of-proprietary-vacdesignr-computational-tool-to-optimize-individualized-therapeutic-cancer-vaccines/</loc><lastmod>2026-07-09T13:26:09+02:00</lastmod></url><url><loc>https://www.transgene.com/sandrine-lemius/</loc><lastmod>2026-03-27T09:01:52+01:00</lastmod></url><url><loc>https://www.transgene.com/feriel-marin/</loc><lastmod>2026-03-27T08:58:54+01:00</lastmod></url><url><loc>https://www.transgene.com/2025-full-year-results-and-business-update/</loc><lastmod>2026-03-16T17:26:07+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-continues-progress-to-reshape-early-stage-cancer-treatment-through-individualized-neoantigen-therapeutic-vaccines-intv-backed-by-financial-visibility-until-early-2028/</loc><lastmod>2026-07-09T13:06:15+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-deliver-an-oral-presentation-on-its-individualized-neoantigen-therapeutic-vaccine-tg4050-at-the-world-vaccine-congress/</loc><lastmod>2026-07-09T13:05:06+02:00</lastmod></url><url><loc>https://www.transgene.com/tg4050-an-individualized-neoantigen-therapeutic-vaccine-in-early-stage-cancer-treatment/</loc><lastmod>2026-04-01T19:03:52+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-nec-bio-sign-license-agreement-to-prepare-the-next-steps-of-the-development-of-tg4050-in-head-and-neck-cancer/</loc><lastmod>2026-07-09T13:03:54+02:00</lastmod></url><url><loc>https://www.transgene.com/synthetic-genome-shuffling-of-poxviruses-via-yeast-tar-cloning-for-next-generation-oncolytic-platforms/</loc><lastmod>2026-04-07T14:47:43+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-participate-in-upcoming-investor-meetings-3/</loc><lastmod>2026-07-09T13:02:48+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-completes-patient-randomization-in-phase-2-part-of-clinical-trial-evaluating-tg4050-in-the-adjuvant-treatment-of-head-and-neck-cancer/</loc><lastmod>2026-07-09T13:01:41+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-provides-business-and-financial-update-for-q1-2026/</loc><lastmod>2026-07-09T13:00:39+02:00</lastmod></url><url><loc>https://www.transgene.com/availability-of-preparatory-documents-for-the-combined-general-meeting-of-may-22-2026/</loc><lastmod>2026-07-09T12:58:19+02:00</lastmod></url><url><loc>https://www.transgene.com/dorothea-ledergerber/</loc><lastmod>2026-05-26T08:48:16+02:00</lastmod></url><url><loc>https://www.transgene.com/solange-peters/</loc><lastmod>2026-05-22T11:48:07+02:00</lastmod></url><url><loc>https://www.transgene.com/transgenes-combined-general-meeting-of-may-22-2026/</loc><lastmod>2026-07-09T12:57:17+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-present-preclinical-data-on-novel-tg-mva-prophylactic-vaccine-against-mpox-at-the-world-congress-on-infectious-diseases/</loc><lastmod>2026-07-09T12:56:02+02:00</lastmod></url><url><loc>https://www.transgene.com/robust-protection-against-monkeypox-virus-mediated-by-a-novel-cell-line-derived-mva-vaccine-tg-mvacl/</loc><lastmod>2026-06-25T07:55:08+02:00</lastmod></url><url><loc>https://www.transgene.com/tg4070/</loc><lastmod>2026-09-24T17:26:49+02:00</lastmod></url><url><loc>https://www.transgene.com/therapeutic-poxviruses-induce-the-secretion-of-immunostimulating-and-anti-tumoral-extracellular-vesicles/</loc><lastmod>2026-06-19T14:18:50+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-expands-myvac-into-non-small-cell-lung-cancer-with-tg4070-an-individualized-neoantigen-therapeutic-vaccine/</loc><lastmod>2026-07-09T12:54:09+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-expands-myvacinto-nsclc-with-tg4070/</loc><lastmod>2026-07-01T10:07:23+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-present-preclinical-data-demonstrating-robust-protection-against-mpox-with-its-novel-scalable-cell-line-derived-mva-vaccine-candidate-tg-mvatm-at-wcid-2026/</loc><lastmod>2026-07-09T12:48:06+02:00</lastmod></url><url><loc>https://www.transgene.com/a-viral-based-individualized-neoantigen-vaccine-as-adjuvant-treatment-in-resected-head-and-neck-squamous-cell-carcinoma-a-randomized-phase-i-trial/</loc><lastmod>2026-09-02T18:04:18+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-nec-report-100-three-year-disease-free-survival-with-tg4050-and-publish-phase-1-results-in-nature-communications/</loc><lastmod>2026-09-02T17:22:04+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-and-probiogen-expand-strategic-partnership-with-additional-license-agreement-for-age1-cr-pix-cell-line/</loc><lastmod>2026-09-07T16:41:25+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-extends-its-myvac-platform-further-establishing-its-position-as-a-key-player-in-the-rapidly-emerging-individualized-cancer-immunotherapy-field/</loc><lastmod>2026-09-24T16:41:52+02:00</lastmod></url><url><loc>https://www.transgene.com/anne-stehlin/</loc><lastmod>2026-09-24T17:50:51+02:00</lastmod></url><url><loc>https://www.transgene.com/katell-bidet-huang/</loc><lastmod>2026-09-24T17:04:40+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-participate-in-investor-access/</loc><lastmod>2026-10-01T16:34:35+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-will-present-a-poster-on-preclinical-data-from-a-novel-oncolytic-virus-at-sitc-2026/</loc><lastmod>2026-10-02T16:04:50+02:00</lastmod></url><url><loc>https://www.transgene.com/synthetic-genome-shuffling-of-poxviruses-in-yeast-generates-novel-poxvirus-candidates-with-potential-oncolytic-properties/</loc><lastmod>2026-10-15T09:17:03+02:00</lastmod></url><url><loc>https://www.transgene.com/transgene-to-present-preclinical-data-on-novel-oncolytic-virus-at-sitc-2026-supporting-its-potential-for-systemic-delivery/</loc><lastmod>2026-11-03T17:45:02+01:00</lastmod></url><url><loc>https://www.transgene.com/poxstg-eev-a-novel-enveloped-virion-based-formulation-of-a-chimeric-oncolytic-poxvirus-adapted-for-systemic-delivery/</loc><lastmod>2026-11-07T15:29:01+01:00</lastmod></url><url><loc>https://www.transgene.com/first-patient-dosed-in-phase-1-trial-evaluating-transgenes-and-bioinvents-bt-001-in-patients-with-rectal-cancer/</loc><lastmod>2026-11-09T16:56:33+01:00</lastmod></url><url><loc>https://www.transgene.com/transgene-reports-continued-clinical-progress-and-q3-2026-financial-update/</loc><lastmod>2026-11-09T16:59:39+01:00</lastmod></url></urlset>

<!--
Performance optimized by W3 Total Cache. Learn more: https://www.boldgrid.com/w3-total-cache/?utm_source=w3tc&utm_medium=footer_comment&utm_campaign=free_plugin


Served from: www.transgene.com @ 2026-11-17 02:50:51 by W3 Total Cache
-->